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Selenium is an essential trace element that has been linked to beneficial health 
effects in multiple disease states.  These effects have been attributed to antioxidant 
activity of selenoproteins; proteins containing selenium incorporated as the amino 
acid selenocysteine during translation of the protein.   
Selenoprotein P is an extracellular glycoprotein containing multiple 
selenocysteine residues. It is the primary selenium distribution protein of the body 
as well as the major selenium containing protein in serum.  An antioxidant function 
has been observed for this protein.  The experiments presented in this dissertation 
were designed to further characterize the mechanisms of selenoprotein P regulation 
and function and test the hypothesis that mechanisms regulating the expression of 
selenoprotein P provide for modulation of this protein so it may function to provide 
antioxidant protection in extrahepatic tissues.   
When stimulated with ecdysone analogs, selenoprotein P expression was 
increased with the use of a fusion transcription factor that contains the 
glucocorticoid receptor DNA binding domain, an ecdysone ligand-binding domain, 
and a strong transactivation domain as well as the retinoid X receptor.  In silico 
analysis of the selenoprotein P promoter identified putative glucocorticoid and 
retinoid responsive binding sites. Luciferase reporter assays 
and quantitative PCR were used to measure selenoprotein P transcription in 
engineered HEK-293 cells.  The native glucocorticoid receptor inhibited 
selenoprotein P transactivation, and selenoprotein P was further attenuated in the 
presence of dexamethasone. 
These studies also aimed to determine if selenoprotein P possessed 
hydroperoxidase activity against lipid hydroperoxides generated from the 
metabolism of arachidonic acid by 15-lipoxygenase-1.  Enzymatic reduction of 15-
hydroperoxyeicosatetraenoic acid (15-HpETE) by selenoprotein P was observed in 
a NADPH-coupled biochemical assay.  Diphenylpyrenylphosphin was used to 
measure lipid hydroperoxides in human embryonic kidney cells treated with 
selenoprotein P following exposure to 15-HpETE.  Cellular oxidation increased 
with 15-HpETE treatment and selenoprotein P reduced this effect.  These results 
suggest that selenoprotein P can function as an antioxidant enzyme during 
inflammation.   
An increased understanding of the mechanisms regulating selenoprotein P 
expression and activity could provide insight into the way in which selenium exerts 
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RATIONALE FOR EVALUATING REGULATORY  
AND FUNCTIONAL MECHANISMS  





The effects of supplemental selenium intake have been evaluated in multiple 
chronic and acute diseases, including cancer, cardiovascular disease, and 
inflammatory conditions such as sepsis, trauma, and burns.  The mechanism by 
which selenium exerts its effects during disease conditions is not completely 
understood; however, it has been hypothesized to be due to the antioxidant activity 
of selenoproteins. These proteins contain selenium incorporated as the amino acid 
selenocysteine (Sec) during translation of the protein.    Selenoprotein P (SelP) is an 
extracellular selenoprotein containing multiple Sec residues.  It is the major source 
of plasma selenium and a majority of the protein is synthesized in the liver for the 
purpose of selenium distribution.  However, the mRNA is detected in almost all 
tissues, leading to a proposed antioxidant function for the protein.   
Evidence exists for changes in plasma selenium levels following 
glucocorticoid administration, with both increases and decreases observed under 
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different conditions, and it is believed these changes result from redistribution of 
selenium between tissue and plasma.  Additionally, SelP is decreased in the plasma 
of critically ill patients, a population that tends to have increased levels of free 
plasma cortisol.  This led to the question of whether there might be a role for the 
glucocorticoid receptor (GR), a nuclear hormone receptor, in regulating SelP 
expression. 
Data suggests that the antioxidant activity of SelP may be specific for lipid-
derived substrates, as opposed to other sources of reactive oxygen stress.  
Inflammation results in the production of numerous reactive lipid intermediates as a 
result of arachidonic acid (AA) metabolism by cyclooxygenase (COX), 
lipoxygenase (LOX), and cytochrome P450 pathways.  These reactive metabolites 
can damage cellular macromolecules and contribute to the pathogenesis of multiple 
disease states, including cancer.  The ability of SelP to exert enzymatic activity 
against these metabolites is unknown; therefore, experiments were designed to 
determine if SelP displayed lipid hydroperoxidase activity directed at 15-LOX-1-
generated metabolites. 
The experiments presented in this dissertation were designed to further 
characterize the mechanisms of SelP regulation and function.  An increased 
understanding of SelP may provide evidence of the mechanisms by which selenium 
exerts its physiological effects.  This knowledge can then be considered and applied 
in the design and execution of in vitro, animal, and clinical studies aimed at 





Selenium and Selenoproteins 
 
Selenium was first discovered by the Swedish chemist JJ. Berzelius in 1817 
(Alissa et al., 2003) and was demonstrated as an essential trace element in 1957 
(Schwarz and Flotz, 1957).  In 1973, selenium was found to be part of the active 
site of the enzyme glutathione peroxidase (Rotruck et al., 1973) and the vital role of 
the element in humans was first documented in a case-study where supplementation 
was used to successfully treat a muscular dystrophy patient receiving long-term 
parenteral nutrition (Van at al., 1979). 
Selenium is distributed throughout the earth’s crust in rocks, minerals, fossil 
fuels and volcanic material (Lockitch, 1989; Alissa et al., 2003).  Foods supply the 
majority of natural selenium to humans, with selenomethionine as the major dietary 
form of the element (Tinggi, 2008).  Dietary sources of selenium include Brazil 
nuts, kidneys, meats and fish, and breads and cereals (Alissa et al., 2003; Rayman, 
2000).  Selenium concentration in food is dependent on the soil content in which 
plants are grown or animals are raised; therefore, serum selenium levels within 
human populations vary geographically (Ge and Yang, 1993).  Low levels exist in 
Finland, New Zealand, and regions of China (Salonen et al., 1982; Thomson and 
Robinson, 1980; Ge and Yang, 1993), while toxic soil levels have been noted in the 
Enshi County of China (Yang et al., 1989).  Estimated selenium intake in the 
United States ranges from 60-220 µg/day, higher than the daily recommended value 




A narrow therapeutic index exists between the essential nutrient effects of 
selenium and the toxicity of this trace element (Daniels, 1996).  Deficiency has 
been attributed to the development of Keshan disease, a potentially fatal form of 
cardiomyopathy that was first documented in a selenium-deficient region of 
northeast China (Ge and Yang, 1993).  Alternatively, acute selenium intoxication 
results in conditions such as hypotension, tachycardia, abdominal pain, pulmonary 
edema, coma and death, while chronic selenium poisoning presents as alopecia and 
nail changes (Nuttall, 2006).  
Both inorganic and organic selenium are utilized as nutrients in mammals 
(Alissa et al., 2003) and are readily metabolized to various forms of selenium 
metabolites (Brenneisen et al., 2005, Ip, 1998) (Figure 1.1).  Hydrogen selenide 
plays a central role in this metabolism (Brenneisen et al., 2005), as inorganic 
selenate and selenite are reduced to hydrogen selenide by selenoglutathione and 
glutathione selenopersulfide and the organic compounds selenomethionine and Sec 
are metabolized to hydrogen selenide by beta-lyase (Ip, 1998).  Further metabolism 
of hydrogen selenide leads to methylation products that are excreted in the breath or 
urine.  Alternatively, hydrogen selenide can serve as a selenium precursor in 
selenoprotein synthesis (Brenneisen et al., 2005, Ip, 1998). 
Selenoproteins are selenium containing proteins in which selenium atoms are 
incorporated as the amino acid Sec.  Sec differs from cysteine in containing a 
selenium, rather than sulfur, atom.  While these two amino acids share many 
chemical properties, the lower pKa of Sec makes it much more reactive than 









Figure 1.1 Selenium metabolism.  Hydrogen selenide  (H2Se) is formed either by 
reduction of the inorganic compounds selenate and selenite or by metabolism of the 
organic compounds selenomethionine and selenocysteine.  H2Se serves as a 
selenium precursor for selenoprotein synthesis or can be methylated to excretion 
products. 
Selenate        
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1991).  As this codon is typically translated as a termination codon, several factors 
are required to ensure specific incorporation of Sec. Key players in this process 
include the Sec specific transfer RNA (tRNA[Ser]Sec) (Lee et al., 1989), the Sec 
insertion sequence (SECIS) found in the 3’ untranslated region of selenoprotein 
mRNAs (Berry et al., 1991),  the Sec specific elongation factor (eEFsec) 
(Fagegaltier et al., 2000), and the SECIS binding protein 2 (SBP2) (Copeland et al., 
2000).  Additional factors shown to be involved include the ribosomal protein L30 
(Chavette et al., 2005), soluble liver antigen (SLA) (Gelpi et al., 1992), and SECp43 
(Ding and Grabowski, 1999). These factors work together to form protein 
complexes that recruit tRNA[Ser]Sec to the mRNA and present the tRNA to the 
ribosome, allowing for Sec translation rather than termination at the UGA codon 
(Small-Howard et al., 2006) (Figure 1.2). 
Twenty-five selenoproteins have been identified in the human genome thus 
far; however, the functions of many of these are still unknown (Lu and Holgren, 
2009).  Functions that have been identified suggest selenoproteins act in a variety of 
biological processes.  The deiodinases are selenoproteins that function in production 
and activation of thyroid hormones (Kuiper et al., 2005; Bianco and Larsen, 2005).  
Several selenoproteins are also involved in providing cellular antioxidant defense 
(Steinbrenner and Sies, 2009).  The glutathione peroxidases (GPx) are some of the 
best characterized antioxidant selenoproteins, protecting cells from reactive oxygen 
and nitrogen species including hydrogen peroxide, nitric oxide, peroxynitrite, free 
fatty acid hydroperoxides, and phospholipid hydroperoxides (Klotz et al, 2003; 







Figure 1.2 Selenocysteine (Sec) translation.  Soluble liver antigen (SLA) and 
SECp43 associate with the Sec transfer RNA (tRNA[Ser]Sec) and the complex 
undergoes nuclear transport, as does  the Sec specific elongation factor (eEFsec) 
and the SECIS binding protein 2 (SBP2).  The stem loop structure making the Sec 
insertion sequence (SECIS) element is found downstream of the stop codon.  The 
SECIS binds SBP2, which subsequently binds eEFSec.  SLA and SECp43 dissociate 
from tRNA[Ser]Sec and eEFSec recruits the tRNA[Ser]Sec carrying selenocysteine.  The 
transfer RNA is presented to the ribosome as it translates the UGA codon, allowing 























also function in cellular redox homeostasis by reducing thioredoxin and other 
substrates (Tamura and Stadtman, 1996).  Evidence has also suggested an 
antioxidant function for SelP (Burk et al., 1995; Arteel et al., 1998; Saito et al., 
1999; Traulsen et al., 2004).  Other selenoproteins that have been less extensively 
characterized include selenoprotein Sep15, selenoprotein R, and selenoprotein W, 
which play roles in glycoprotein folding, reduction of methionine sulfoxides, and 
muscle function, respectively (Lu and Holmgren, 2009; Allan et al., 1999). 
A hierarchy exists among selenoproteins for utilization of available selenium 
(Brigelius-Flohé, 1999).  This hierarchy is twofold during selenium-deficiency in 
that 1) there is preferential tissue expression and activity of selenoproteins and 2) 
specific selenoproteins are preferentially synthesized within a particular tissue 
(Gross et al., 1995; Lu and Holmgren, 2009).  Preference for selenium retention or 
accumulation is observed in tissues such as the brain, reproductive organs, and 
endocrine glands (Burk et al., 1972; Behne et al., 1988), while the activities of most 
selenoproteins are decreased in the liver, kidney, and lung under selenium deficient 
conditions (Lu and Holmgren, 2009).  Cytosolic GPx mRNA and protein levels 
decrease rapidly in the liver when selenium levels are low; however, phospholipid 
hydroperoxide GPx and thioredoxin reductase are maintained at higher levels 
(Brigelius-Flohé, 1999).  In porcine epithelial kidney cells, preference for 5’-
deiodinase expression over cytosolic GPx was observed when selenium supply was 
low (Gross et al., 1995).  In the liver of rats, SelP and 5’-deiodinase mRNA levels 
remain higher than cytosolic GPx when animals were fed a selenium-deficient diet 
(Hill et al., 1992).  Additionally, the level of selenium required to increase plasma 
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SelP concentration in rats is lower than the level required to restore cytsolic GPx 
activity following selenium-deficiency (Yang et al., 1989).  This hierarchal 
expression of selenoproteins may be based on biological significance of the protein, 
with changes in activity likely being the result of a decrease in selenium 
incorporation into the protein (Gross et al., 1995).  Adequate selenium intake is 
therefore important in maintaining proper translation and function of the 
selenoproteins (Wingler et al., 1999; Bermano et al., 1995).  
 
Beneficial Health Effects of Selenium 
 
Supplemental selenium intake has been evaluated in multiple chronic and 
acute diseases (Clark et al., 1996; Mark et al., 2000; Nomura et al., 2000; Brown & 
Arthur, 2001; Angstwurm & Gaertner, 2006; Angstwurm et al., 2007) and one 
mechanism by which selenium is hypothesized to exert its beneficial health effects 
is through the enzymatic activity of selenoproteins. (Diwadkar-Navsariwala & 
Diamond, 2004; Irons et al., 2006, Diwadkar-Navsariwala, 2006).  Meta-analysis 
has shown reduced all-cause mortality when supplements containing selenium were 
used (Bjelakovic et al., 2007); however, it appears this effect may be specific to 
individuals with low plasma selenium levels (Bleys et al., 2008).  
Serum selenium levels have been shown to be inversely correlated to the 
incidence of certain cancers (Clark et al., 1996; Clark et al., 1993; Mark et al., 
2000).  Dietary supplementation with 200µg/day selenium in the form of enriched 
yeast has led to decreased cancer mortality and a lower incidence of various types 
of secondary cancers (Clark et al., 1996).  These results led to the Selenium and 
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Vitamin E Cancer Prevention Trial (SELECT), a double-blind, randomized, 
placebo-controlled clinical trial designed to determine whether selenium, vitamin E, 
or the combination could prevent prostate cancer (Lippman et al., 2009).  The trial 
was terminated early when it was found that there was no difference in the rates of 
prostate cancer between the treatment groups and a nonsignificant increase in 
diabetes mellitus was observed in the selenium group. 
Despite the increased incidence of type 2 diabetes following long-term 
supplementation with selenium (Stranges et al., 2007; Lippman et al., 2009), there 
is evidence suggesting potential beneficial effects of selenium in diabetes.  Relative 
selenium deficiency was previously suggested to be associated with diabetes 
(Rajpathak et al., 2005).  Additionally, animal studies have shown that 
supplementation with low doses of selenium may delay complications of diabetes 
through an improvement in glucose metabolism (Stapleton, 2000; Sheng et al., 
2004; Mueller and Pallauf, 2006).  The incidence of vascular complications of 
diabetes was also shown to be decreased with selenium supplementation (Faure et 
al., 2004). 
Low serum selenium and decreased SelP concentrations have been associated 
with an increased risk of cerebrovascular events (Koyama et al., 2009).  While 
meta-analysis shows an inverse correlation between selenium concentration and 
coronary heart disease (Flores-Mateo et al., 2006), no association has been found 
between selenium levels and cardiovascular mortality (Bleys et al., 2008).   
Adequate selenium availability also appears to be important in proper immune 
function, with supplementation enhancing proliferation and activity of immune cells 
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(Rayman, 2000).  Specifically, plasma selenium levels are significantly decreased in 
critically ill patients and this correlates with severity of disease (Forceville et al., 
1998).  A meta-analysis evaluating the effect of antioxidants in critically ill patients 
revealed a trend toward reduced mortality with selenium supplementation (Heyland 
et al., 2005), and this was confirmed in the Selenium in Intensive Care trial, which 
showed a 10.3% reduction in 28-day mortality rate in patients receiving 1000µg 
sodium selenite per day (Angstwurm et al., 2007). 
While selenium is acknowledged as an essential nutrient for humans, the exact 
role of this element in various disease states is not yet fully understood.  Despite the 
beneficial effects that have been noted under numerous disease conditions, it 
appears that much of the data are conflicting and inconclusive.  Therefore, further 
studies are required in order to fully elucidate the mechanism and extent of 





SelP was the second animal selenoprotein to be identified, following cytosolic 
GPx (Burk and Hill, 2005).  It was first discovered in rat plasma in 1977 (Herrman, 
1977) and found to contain selenium in the form of Sec in 1982 (Motsenbocker and 
Tappel, 1982).  Purification of the protein was finally achieved in 1987 using 
immobilized monoclonal antibodies (Yang et al., 1987).  Because no function could 
be attributed to the protein at the time of its discovery, the letter P was used to 
signify its localization to the plasma (Burk and Hill, 2005). 
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Genomic sequences have been reported for the both the murine and human 
SelP gene (SEPP1) (Steinert et al., 1998; Yasui et al., 1996), and cDNA encoding 
analogs in additional species have been sequenced (Hill et al., 1991; Saijoh et al., 
1995; Kryukov and Gladyshev, 2000).  SEPP1 appears to be expressed only in 
vertebrates, as the gene was not found in Caenorhabditis elegans or Drosophila 
melanogaster (Kryukov et al., 2003).  The human gene is 12kb and contains five 
exons, with the translational start site in the second exon (Yasui et al., 1996).  The 
gene has ten UGA codons coding for Sec, with one found in the second exon and 
the remaining nine found in the fifth exon.  Two functionally distinct SECIS 
elements also exist in the fifth exon (Berry et al., 1993).  These features are unique 
to SEPP1, as other selenoproteins contain just one Sec residue and one SECIS 
element.  A complex translational process involving an inefficient decoding step at 
the N-terminal UGA by the 3’-proximal SECIS is required to ensure the 
incorporation of multiple Sec residues into SelP (Stoytcheva et al., 2006). This 
inefficiency at the first UGA seems to serve as a checkpoint at which the presence 
of components required for Sec incorporation can be verified prior to translation of 
the remaining nine Sec residues by the additional SECIS element.  If conditions are 
not favorable for Sec translation, such as might occur during selenium deficiency, 
then the mRNA will undergo nonsense-mediated decay. 
 The amino acid sequence of SelP deduced from rat liver cDNA contains 366 
residues with a predicted peptide weight of 41,052 Da (Hill et al., 1991).  There are 
10 Sec, 17 cysteine, and 28 histidine residues within the polypeptide (Read et al., 
1990; Hill et al., 1991).  Two domains exist with regard to selenium content.  The 
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N-terminal 244 residues include one Sec while the 122 amino acid C-terminal 
domain contains nine (Saito et al., 2004).  Two histidine-rich regions exist at 
residues 185-198 and residues 225-234, and multiple disulfide and selenenylsulfide 
linkages are found throughout the protein (Burk and Hill, 2005; Ma et al., 2003, Ma 
et al., 2005). SelP binds heparin at pH 7.0 and becomes unbound as pH is raised 
toward 8.5 (Chittum et al., 1996).  A motif located at residues 80-95, a region that 
includes three lysine and three histidine residues, is responsible for the majority of 
heparin binding (Hondal et al., 2001).  Three N-glycosylation sites and one O-
glycosylation site have been identified (Ma et al., 2003).  These carbohydrate 
additions to the protein account for discrepancies in molecular mass measurements 
between the predicted weight and weight observed by mass spectrometry or SDS-
PAGE, which show the native protein at approximately 57,000 Da (Read et al., 
1990; Ma et al., 2003) (Figure 1.3). 
Protein purified from rat serum showed an average of 7.5 + 1 atom of selenium per 
molecule SelP (Read et al., 1990).  Inconsistency between the number of predicted 
Sec residues and the number of selenium atoms measured in purified protein has 
been attributed to the existence of multiple SelP isoforms (Himeno et al., 1996; Ma 
et al., 2002).  In addition to the full length protein with ten Sec incorporated, three 
shorter isoforms have been observed that all share the N-terminus sequence of the 
full length protein, but terminate at the second, third, or seventh UGA (Ma et al., 
2002).  Because these isoforms share an N-terminal sequence and only one SEPP1 



















Figure 1.3 Selenoprotein P protein features.  (A) Representation of the amino 
acid sequence of rat selenoprotein P.  Selenocysteine residues are shown in black 
and cysteine residues are shown in gray.  The heparin-binding site is indicated by 
spotted circles and histidine rich regions are shown with hashed circles.  CHO 
indicates N- and O- glycosylation sites.  Selenenylsulfide and disulfide bonds are 
represented by lines connecting the respective amino acid residues.  (B) Two 
domains exist in regards to the selenium content of selenoprotein P.  One Sec 
residue is found in the N-terminal domain that is believed to be responsible for the 
antioxidant activity of the protein, while the remaining nine Sec residues are 
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isoforms result from alternative translation of the UGA codons as Sec or stop 
codons (Burk and Hill, 2005). 
The regulation of SEPP1 expression is an active area of investigation with 
changes noted under a broad spectrum of biological processes. Promoter activity 
has been shown to be inhibited by cytokines including interleukin 1β, tumor 
necrosis factor α, interferon γ, and transforming growth factor β1 (Dreher et al., 
1997; Mostert et al., 2001). Decreased SEPP1 expression has been observed with 
neoplastic progression from normal tissue to carcinoma to metastatic disease in 
cells of prostate origin (Dhanasekaran et al., 2001).  Evaluation of SEPP1 
expression in the Oncomine database (Rhodes et al., 2004) also identifies decreased 
SEPP1 expression in melanoma, lung, and colon cancer compared to normal tissue 
suggesting that decreased SEPP1 expression may be a common feature of 
malignancies.  Increased expression has been observed in differentiating myeloid, 
pulmonary, and Sertoli cells (Tabuchi et al., 2005; Ghassabeh et al., 2006; Wade et 
al., 2006). Alternatively, promoter activity is stimulated in hepatic cells through a 
mechanism involving the collaboration of the coactivator peroxisomal proliferator  
activated receptor-γ coactivator 1α (PCG-1α), the forkhead box transcription factor 
FOXO1a, and the hepatic nuclear factor 4α (HNF-4α) transcription factor 
(Speckmann et al., 2008; Walter et al., 2008).  
The majority of SelP is derived from hepatic sources; however, the mRNA 
can be detected in almost all tissues, with appreciable concentrations observed in 
the kidney, heart, lung, brain, skeletal muscle, and testis (Burk and Hill, 2005).  
SelP is, for the most part, an extracellular protein; however, intracellular 
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localization within human astrocytes (Steinbrenner et al., 2006 a) and Purkinje cells 
(Schweizer et al., 2004) has been reported.  The plasma concentration of SelP is 
approximately 5-6 mg/L in humans (Burk and Hill, 2005) and the protein accounts 
for more than 50% of the selenium content of human plasma (Saito and Takahashi, 
2002). A plasma half-life of 4 hours is consistent with a high turnover rate for this 
protein (Burk et al., 1991). 
SelP is strongly associated with endothelial cells in the liver, kidney, and brain 
(Burk et al., 1997) and saturable binding to membranes has been observed in 
various organs (Wilson et al., 1993).  Receptor-mediated uptake of SelP has been 
confirmed in the testis and kidney, where apolipoprotein E receptor-2 (ApoER2) 
and megalin, are responsible for protein uptake, respectively (Olson et al., 2007; 
Olson et al., 2008).  Additionally, ApoER2 has been suggested to interact with SelP 
in the brain (Burk et al., 2007).  Heparin binding by SelP is also thought to provide 
a mechanism for localizing or binding SelP to specific structures for the purpose of 
functioning in distinct biological processes.  Specifically, as a result of the pH 
dependence of heparin binding, SelP may localize under acidic conditions, such as 
sites of inflammation (Hondal et al., 2001) 
SelP appears to be a bifunctional protein with two functionally distinct 
domains (Saito et al., 2004; Burk and Hill, 2009). The N-terminal domain possesses 
the first Sec residue and is thought to be responsible for antioxidant activity.  The 
remaining nine Sec are found in the C-terminal domain that is thought to function in 
selenium distribution (Saito et al., 2004) (Figure 1.3).  
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SelP functions as a selenium supplier and has been shown to be more effective 
in supplying selenium to cells than plasma GPx, selenocystine, sodium selenite, or 
selenomethionine (Saito and Takahashi, 2002).  SelP knockout mice display altered 
selenium distribution, particularly to the testes and brain (Hill et al., 2003; Burk et 
al., 2006).  The knockout phenotype also consists of significant neurological 
dysfunction and male infertility when the animals are fed a selenium-deficient diet 
(Hill et al., 2003).  Dietary supplementation prevents neurological impairment (Hill 
et al., 2004); however, male infertility, resulting from structural defects during 
spermiogenesis, persists regardless of selenium status (Olsen et al., 2005).  This 
suggests that the brain has an alternative mechanism beyond SelP for acquiring 
selenium, but that the testes do not. The C-terminal region of SelP was shown to be 
critical in the delivery of selenium to the brain and testes (Hill et al., 2007), lending 
further support to the selenium distribution function of this domain.  Additionally, 
transgene expression of hepatic SEPP1 in knockout mice restores selenium 
transport to these two tissues and prevents neurological disturbances and male 
infertility (Renko et al., 2008).   
Biochemical data has supported a role for SelP as a phospholipid 
hydroperoxidase (Saito et al., 1999; Takebe et al., 2002), with the N-terminal 
domain implicated in this antioxidant activity (Saito et al., 2004).  Further evidence 
of the antioxidant activity of SelP includes protection against diquat-induced 
oxidative liver damage in rats (Burk et al., 1995) and inhibition of low-density 
lipoprotein oxidation (Traulsen et al., 2004).  Lipid hydroperoxides have been 
shown to increase in myofibroblasts when SelP expression is knocked down 
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(Kabuyama et al., 2007). Additionally, SelP protected against tert-butyl 
hydroperoxide (t-BHP)-induced cytotoxicity in endothelial cells and astrocytes 
when the cells were maintained in selenium deficient medium (Steinbrenner et al., 
2006 a; Steinbrenner et al., 2006 b).  
Lastly, SelP is also proposed to function as an acute phase protein due to its 
negative regulation by cytokines (Dreher et al., 1997; Mostert et al., 2001).  This 
hypothesis is supported by the observation that plasma SelP concentration is 
reduced in septic patients (Hollenbach et al., 2008; Forceville et al., 2009).  These 
patients tend to have increased levels of free plasma cortisol (Hamrahian et al., 
2004), introducing the possibility that glucocorticoids could potentially play a role 
in regulating SelP during the acute phase of inflammation. 
 
 
Glucocorticoids and Nuclear Receptors 
 
The glucocorticoid receptor is a member of the nuclear receptor superfamily, 
a family of which there are more than 150 different members ranging across various 
evolutionary species (Mangelsdorf et al., 1995).  Additional receptors of this 
superfamily include mineralocorticoid, estrogen, progesterone, and androgen 
steroid receptors, the retinoic acid receptor (Giguére et al., 1987; Petkovich et al., 
1987), the retinoid X receptor (RXR) (Mangelsdorf et al., 1990), a receptor for 
thyroid hormones (Sap et al., 1986; Weinberger et al., 1986), and the Drosophila 
ecdysone receptor (EcR) (Koelle et al., 1991). 
These receptors contain three functional domains: a variable N-terminal 
domain, a DNA-binding domain (DBD), and a C-terminal ligand binding domain 
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(LBD) (Mangelsdorf et al., 1995).  The N-terminal domain contains a strong 
transactivation domain thought to be involved in gene regulation; the DBD 
specifies receptor binding to target DNA sequences through two highly conserved 
zinc fingers; and the LBD ensures specific and selective physiological 
consequences of receptor activation by mediating ligand recognition (Mangelsdorf 
et al., 1995; Lu et al., 2006; Kumar and Thompson,1998). 
A key characteristic of these receptors is their ability to function as ligand-
inducible transcription factors (Germain et al., 2006; Teboul et al., 2008).  In the 
absence of ligand, the GR remains localized to the cytoplasm, where is bound by 
various chaperone proteins.  Ligand binding results in conformational changes that 
release chaperone proteins and induce translocation of the receptor to the nucleus 
(Schimmer and Parker, 2009).  The receptor then dimerize as homo- or hetero-
dimers, recruit transcriptional coactivator proteins, and bind DNA response 
elements composed of two core hexameric motifs (Schimmer and Parker, 2009; 
Aranda and Pascual, 2001).  This mechanism allows for modulation of gene 
expression, with target genes dictated by cell and tissue specific conditions (Lu et 
al., 2006) (Figure 1.4).  
The GR, as well as other steroid receptors, bind to palindromes of the 
consensus sequence AGAACA.  The consensus sequence for non-steroid nuclear 
receptors  is AG(G/T)TCA (Aranda and Pascual, 2001).  Multiple nuclear receptor 
types can bind these sequences and mediate transcriptional activity, allowing for 
differential control of overlapping gene networks (Bedo et al., 1989; Umesono et 







Figure 1.4 Mechanism of glucocorticoid receptor signaling.  The GR consists 
of a ligand binding domain (LBD) and DNA binding domain (DBD).  Under 
basal conditions, the receptor is maintained in the cytoplasm through interactions 
with chaperone proteins.  Ligand binding results in loss of chaperone protein 
interactions and translocation of the receptor into the nucleus.  Once in the 
nucleus, the receptors dimerize, recruit coactivator proteins, and bind to 
glucocorticoid response elements (GRE) in the promoter region of target genes.  
Resulting modulation of gene expression produces the varying physiological and 
therapeutic effects of glucocorticoids. 
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glucocorticoid response element (GRE) has been shown to be sufficient for activity 
when acting synergistically with other transcription factors or when the response 
element is located in close proximity to the TATA box (Strähle et al., 1988).   
Alternative splicing leads to multiple isoforms of the GR, with GRα and GRβ 
among the best characterized (Lu and Cidlowski, 2005).  The GRα isoform appears 
to be responsible for inducing transcription of target genes through its ability to 
bind both ligands and GREs.  Alternatively, the GRβ isoform does not bind DNA 
despite being capable of dimerization.  Heterodimerization of GRβ with GRα 
interferes with the function of the α isoform (Lu and Cidlowski, 2004).  The GR is 
expressed in almost all tissues; however, tissue-specific expression of the isoforms 
has been observed (Pujols et al., 2001; Oakley et al., 1996; Lu and Cidlowski, 
2005). 
Glucocorticoid synthesis and secretion occurs in the adrenal cortex through a 
process regulated by negative feedback on the hypothalamic-pituitary-adrenal axis.  
Cortisol is the major endogenous glucocorticoid in humans and a total of 
approximately 10 mg is secreted daily.  Secretion occurs in a diurnal manner with 
total serum concentration ranging from 16 µg/dL in the morning to 4 µg/dL in the 
evening (Schimmer and Parker, 2009).  Cortisol is highly protein bound in the 
plasma and only free circulating cortisol is considered to be biologically active 
(Mueller and Potter, 1981; Rhen and Cidlowski, 2005).  Consequentially, 
alterations in serum protein levels can increase the availability of free cortisol 
capable of exerting activity on target cells (Hamrahian et al., 2004). 
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Through their ability to modulate gene expression, nuclear receptors play a 
pivotal role in some of the most fundamental aspects of physiology (Lu et al., 
2006).  Specifically, glucocorticoids work in regulation of carbohydrate, protein, 
and fat metabolism; preservation of normal function of the cardiovascular system, 
the immune system, the kidney, skeletal muscle, the endocrine system, and the 
nervous system; and protection against stressful stimuli such as injury, hemorrhage, 
severe infection, major surgery, hypoglycemia, cold, pain, and fear.  
Glucocorticoids also play a vital role in growth and development (Schimmer and 
Parker, 2009). 
As a result of their diverse biological activity, glucocorticoids are used 
therapeutically in several disease states.  Chemical modification of the cortisol 
molecule has led to the development of synthetic glucocorticoids, such as 
prednisone, methylprednisolone, and dexamethasone (Dex), which have 
characteristics favorable for therapeutic use, including increased specificity, 
potency, and duration of action. With the exception of treatment for adrenal 
insufficiency, the therapeutic use of glucocorticoids is considered empirical 
(Schimmer and Parker, 2009).    Immunomodulatory activity of glucocorticoids 
lends to their use in infections, allergies, pulmonary disease, and inflammatory 
conditions (Lu et al., 2006; Schimmer and Parker, 2009).  They are also used in the 
treatment of certain leukemias and added to chemotherapeutic regimens for their 
antiemetic, antiedema, and palliative properties (Schimmer and Parker, 2009).    
Prolonged therapy can cause serious side effects, including immunosuppression, 
osteoporosis, glaucoma, metabolic syndrome, impaired development, and 
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psychological disturbances (Rhen and Cidlowski, 2005; Schimmer and Parker, 
2009). 
Evidence exists for changes in plasma selenium levels following 
glucocorticoid administration, with both increases and decreases noted under 
different sets of conditions (Peretz et al., 1987; Marano et al., 1990; Watanabe et 
al., 1997). Although the effect of glucocorticoids on selenium levels has not been 
fully characterized, it is believed that these changes result from redistribution of 
selenium between tissue and plasma. Tissue-specific modifications in selenium 
concentration have been observed in mice treated with Dex, with increases seen in 
the plasma and cerebrum, decreases observed in the liver, and no effect observed in 
the kidney, muscle, heart, cerebellum, or brain stem (Watanabe et al., 1997).  
Selenium redistribution to high priority organs has also been proposed as a 
mechanism for changes in plasma selenium observed in critically ill patients 
(Forceville et al., 1998) and these patients tend to have increased levels of free 
plasma cortisol (Hamrahian et al., 2004).  It is unknown what role SelP may play in 
glucocorticoid-induced selenium redistribution; however, a reduction in plasma 
SelP concentration is observed in septic patients (Hollenbach et al., 2008; Forceville 
et al., 2009).    
 
 
Inflammation and Oxidative Stress 
 
Inflammation occurs in response to tissue injury resulting from insults such as 
infection or mechanical injury (Burke et al., 2009).  It is a localized response aimed 
at destroying, diluting, or walling-off the site of injury (Gallin and Snyderman, 
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1999).  Activation and migration of leukocytes to the site of damage is a hallmark 
feature of inflammation (Coussens and Werb, 2002; Gallin and Snyderman, 1999).  
Cytokines including tumor necrosis factor α and transforming growth factor β work 
to orchestrate the inflammatory response through chemoattraction of specific 
leukocyte populations and phagocytic cells (Burke et al., 2009; Coussens and Werb, 
2002). 
During this process, cytokines, as well as other inflammatory stimuli, also 
initiate the release of polyunsaturated fatty acids, such as arachidonic acid (AA), 
from membrane phospholipids (Fitzpatrick and Soberman, 2001).  Once released 
from the cell membrane by phospholipase A2 enzymes, these lipids are metabolized 
to bioactive eicosanoids through one of four separate pathways (Smyth and 
FitzGerald, 2009) (Figure 1.5).  Prostaglandin synthesis occurs through metabolism 
by the cyclooxygenase (COX) pathway (Parente and Perretti, 2003).  The 5-, 12-, 
and 15-lipoxygenase (LOX) enzymes metabolize AA to hydroperoxy-
eicosatetraenoic acids (HpETE), which are rapidly converted to hydroxy derivatives 
(HETEs) and leukotrienes (Natarajan and Nadler, 2004; Sordillo et al., 2008).  AA 
is converted to hydroxy- and epoxy-eicosatrienoic acids by specific cytochrome 
P450 isozymes and the isoeicosanoids are formed by nonenzymatic peroxidation of 
AA (Smyth and FitzGerald, 2009).   
The oxidative metabolites produced by these pathways are known as reactive 
oxygen species (ROS).  In addition to the lipid radicals formed from AA, 
alternative ROS include the superoxide anion, hydroxyl radicals, hydrogen 









Figure 1.5 Arachidonic acid metabolism.  Nonenzymatic peroxidation of AA 
produces isoeicosanoids.  Oxidation by COX, LOX, or cytochrome P450 enzymes 
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levels, ROS can modulate signal transduction pathways; however, an 
overabundance of ROS can lead to oxidative stress that damages cellular 
macromolecules including DNA, protein, and lipids (Brenneisen et al., 2005).  For 
this reason, ROS have been linked to the pathogenesis of multiple diseases, 
including cardiovascular disease, neurodegenerative diseases, and cancer 
(Steinbrenner and Sies, 2009). 
 Excessive inflammation resulting from a prolonged inflammatory reaction or 
abnormal recognition of an injury is therefore considered a risk factor for disease 
development as a result of ROS formation (Coussens and Werb, 2002; Gallin and 
Snyderman, 1999). Specifically, a relationship between chronic inflammation and 
carcinogenesis has been noted in numerous malignancies, including colon cancer 
and hepatocellular carcinoma (Itzkowitz et al., 2004; Macarthur et al., 2004).  It is 
believed that leukocytes and other phagocytic cells involved in the inflammatory 
process may lead to an induction of DNA damage in proliferating cells through the 
production of reactive oxygen and nitrogen species (Maeda and Akaike, 1998; 
Coussens and Werb, 2002).  Additionally, enzymes expressed during the 
inflammatory process have been shown to be upregulated in certain cancers (Gupta 
et al., 2001; Kelavkar et al., 2000) and membrane lipids released and metabolized 
during inflammation have been linked to various malignancies, including prostate 
cancer (Hursting et al., 1990).  In addition, end products of lipid peroxidation have 
been implicated as being mutagenic (Ray et al., 2002), further contributing to 
evidence that inflammation may result in carcinogenesis through its ability to 
increase the oxidative tone of the cellular environment.  
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Cells possess a series of enzymatic and non-enzymatic antioxidant systems for 
detoxifying ROS and repairing the oxidative damage they cause.  In addition to 
superoxide dismutases and catalase, the selenoproteins, and specifically the 
glutathione peroxidases, are among the most important intracellular antioxidant 
enzymes (Steinbrenner and Sies, 2009).   An antioxidant function has been 
observed for SelP (Burk et al., 1995; Arteel et al., 1998; Saito et al., 1999; Traulsen 
et al., 2004), and while this activity seems to be specific for phospholipid 
hydroperoxides versus other forms of oxidative stress, it is unknown whether SelP 





Selenoprotein P is an extracellular glycoprotein that functions both in 
selenium distribution and has antioxidant activity.  The following studies were 
designed to further characterize this protein, both in regards to mechanisms 
regulating expression and antioxidant function. 
Chapter 2 describes the in silico evaluation of putative transcription factor 
binding sites within the selenoprotein P promoter.  The results of this evaluation 
were confirmed in vitro with the use of luciferase reporter assays, quantitative 
polymerase chain reaction, and electrophoretic mobility shift assay.  These 
experimental approaches aimed to characterize the regulation of selenoprotein P 
through glucocorticoid response elements and the results are described in Chapter 3 
of this dissertation. 
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Chapter 4 outlines work aimed at determining the role of selenoprotein P in 
regulating the cellular oxidative stress induced by reactive hydroperoxylipid 
intermediates.  Biochemical reduction of 15-HpETE by SelP, as well reduction of 
lipid hydroperoxides in cells exposed to 15-HpETE were evaluated.   
Collectively, the studies presented were aimed at testing the hypothesis that 
mechanisms regulating the expression of selenoprotein P provide for modulation of 








Electronic database analyses were able to identify multiple putative 
transcription factor binding sites in the selenoprotein P promoter.  Specifically, 
glucocorticoid and retinoid responsive elements that could be involved in gene 





When stimulated with ecdysone analogs, selenoprotein P expression was 
increased with the use of a fusion transcription factor that contains the 
glucocorticoid receptor DNA binding domain, an ecdysone ligand-binding domain, 
and a strong transactivation domain as well as the retinoid X receptor.  The native 
glucocorticoid receptor inhibited selenoprotein P transactivation, and selenoprotein 
P was further attenuated in the presence of dexamethasone.  Putative glucocorticoid 
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and retinoid responsive elements in the selenoprotein P promoter were responsible 




Enzymatic reduction of 15-HpETE by selenoprotein P was observed in a 
NADPH-coupled biochemical assay.  Lipid hydroperoxides increased with 15-
HpETE treatment of cells, and SelP reduced this affect both when the protein and 
metabolite were added simultaneously, and in a transcellular assay when 15-LOX-1 
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DISCOVERY OF PUTATIVE TRANSCRIPTION FACTOR 
 
BINDING SITES IN SELENOPROTEIN P USING 
 






Gene regulation at the transcriptional level is activated or repressed by 
binding of transcription factors to short DNA sequences known as transcription 
factor binding sites (TFBS) (Novina and Roy, 1996; Sandelin and Wasserman, 
2004).  These sites typically range in size from ~5-12 base pairs and can show 
significant variability in sequence, while still remaining a functional binding site for 
transcription factors (Sandelin et al., 2004). Difficulty arises when attempting to 
discover these regulatory regions within the promoter region of a gene of interest, 
as binding sites tend to be short and degenerate, while being widely distributed over 
several thousand base pairs.  Additionally, promoter regions in general can often be 
difficult to precisely identify (Sandelin et al., 2004; Bailey et al., 2006).  Therefore, 
multiple computational systems have been developed to aid in identifying putative 
TFBS within a given DNA sequence (Elnitski et al., 2006).    
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When used in concert, these systems can work synergistically to provide 
multiple lines of evidence regarding the regulatory mechanisms controlling 
expression of a gene or a series of genes.  TRED (Transcriptional Regulatory 
Element Database) is a database of both cis- and trans- regulatory elements that 
serves as a resource for studying gene regulation and function.  TRED cross-
references with other databases, including PubMed, GenBank, GeneCards, and 
TRANSFAC, so as to provide users with more complete information regarding 
genes of interest (Jiang et al., 2007).  TRANSFAC is a complementary database to 
TRED, providing factor-site interaction data for multiple species (Matys et al., 
2003).  TESS (Transcriptional Element Search Software) is a web-based software 
tool that uses TRANSFAC as a source of raw data about transcription factors and 
preprocesses the TRANSFAC files to create indexed tables that are easier to access 
and analyze. TESS works to align model binding sites with a user-defined DNA 
sequence, allowing for identification of possible TFBS in DNA sequences (Schug 
and Overton, 1997).  
GATHER (Gene Annotation Tool to Help Explain Relationships) integrates 
information from multiple data sources so as to elucidate a biological context for 
molecular signatures produced from high-throughput assays, such as microarrays 
(Chang and Nevins, 2006).  This creates annotations that identify potential shared 
regulatory mechanisms and functions among the genes of a particular molecular 
signature.  The inclusion of a Bayesian statistical model provides a novel analytical 
method that increases the accuracy of annotations defined by GATHER. A positive 
Bayes factor indicates that evidence supports the association between the annotation 
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and the signature, and the magnitude corresponds to the strength of the evidence for 
the association, where higher values are stronger.  A Bayes factor of at least 6 has 
been recommended to represent a significant annotation (Chang and Nevins, 2006). 
MEME (Multiple EM for Motif Elicitation) allows for the discovery of 
signals, or “motifs”, within DNA sequences of interest (Bailey and Elkan, 1994).  
Users may evaluate a set of sequences for shared sequence signals, with these 
signals potentially indicating TFBS shared among coexpressed genes. Identification 
of these motifs is accomplished by searching for repeated, ungapped sequence 
patterns occurring within the user-defined sequences (Bailey et al., 2006).  Results 
are presented as block diagrams, which show the relative positions of the motifs in 
each of the input sequences, as well as which positions in the motif, displayed as 
columns, are most highly conserved.  Columns are colored according to the 
majority category of the letters occurring in that column of the alignment and a 
multilevel consensus sequence is created based on these probabilities (Bailey, 
2002). The amount of information contained in each position of the motif is 
measured in bits, with highly conserved positions having high information and 
positions where all bases are equally likely having low information.  A sum of the 
information content for each position of the motif provides the total information 
content of the motif, which serves as a measure of the usefulness of the motif in 
database searches such as TESS.  (Bailey and Elkan, 1994; Bailey, 2002).   
Use of these in silico methods can aid in the identification of potential binding 
sites within the promoter region of a gene, but the discovery of such sites does not 
necessarily mean that the site will prove to be a functional regulatory element either 
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in vitro or in vivo.  Phylogenetic footprinting is a technique that can be used to 
improve the detection of functional elements in DNA sequences (Sandelin et al., 
2004; Zhang and Gerstein, 2003).  This technique is based on the concept that the 
selective pressure of evolution will produce a preferential conservation of 
functional regulatory regions in noncoding gene sequences than in regions that have 
no sequence-specific function.  Therefore, if a sequence has remained highly 
conserved during evolution, it is likely that this sequence is functional (Duret and 
Buchert, 1997).  ConSite is a web-based tool that uses this type of comparative 
sequence analysis in the identification of regulatory regions (Lenhard et al., 2003; 
Sandelin et al., 2004).  The major components of the ConSite analysis include 
aligning the orthologous input sequences, calculating the degree of conservation in 
the alignment, scanning the sequences for transcription factor binding profile 
models, filtering the initial sets of sites using phylogenetic footprinting, and 
presenting the results in user-selected output formats (Sandelin et al., 2004). 
When used together, each of the databases described above can serve 
overlapping and complementary functions that provide powerful evidence of 
mechanisms regulating expression of a gene of interest.  This chapter describes the 
use of these computational tools for the identification of potential regulatory 
regions in the selenoprotein P (SEPP1) promoter.  Coexpressed genes were 
identified through microarray analysis and the promoter sequences of these genes 
were entered into the databases in order to identify homologus motifs, determine 
potential TFBS, and search the potential binding sites for evolutionary 
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conservation.  When taken together, this evidence provides specific gene regions 








 The human embryonic kidney (HEK-293) cell line was purchased from 
American Type Culture Collection (Manassas, VA).  Advanced DMEM, CD-293, 
pVgEcR, zeocin and geneticin were purchased from Invitrogen (Carlsbad, CA).  
Ovalbumin was purchased from Fisher Scientific (Pittsburgh, PA).  Ponasterone A 
was purchased from A.G. Scientific (San Diego, CA).  Arachidonic acid was 
purchased from Nu-Check Prep (Elysian, MN).  RNeasy Mini Kit was obtained 





pVgEcR encodes the fusion transcription factor used to generate ecdysone-
inducible cells.  HEK-293 cells were transfected with pVgEcR and selected for 
zeocin resistance to generate stable expression of the VgEcR gene product.  
Ecdysone-inducible cells that conditionally express 15-LOX-1, ∆Ile662 15-LOX-1, 
or 12-LOX have been previously described (Yu et al., 2004; Cordray et al., 2007).  
Conditional expression of β-galactosidase (LacZ) in HEK-293 cells was achieved 
using similar methods.  These engineered cells were maintained at 37°C in a 
humidified incubator with 5% CO2 in Advanced DMEM supplemented with 2% 





Microarray experiments were performed using Agilent 44K (human whole 
genome) oligonucleotide microarrays (Agilent, Santa Clara, CA) and processed on 
site in the Microarray Resource located within the Huntsman Cancer Institute.   
Engineered HEK-293 cells were plated on a 6-well plate at a concentration of 5x105 
cells/well in CD-293 medium containing 2 mM L-glutamine and 0.1% ovalbumin.  
After 24 hours cells were treated with 10 µM ponasterone A (PonA) and incubated 
for 24 hours at 370C to induce expression of 15-LOX-1, ∆Ile662 15-LOX-1, 12-
LOX, or LacZ.  Cells were then treated with 20µM arachidonic acid (AA) for 4 
hours prior to RNA collection.  Sufficient total RNA was recovered using the 
Qiagen RNeasy minikit protocol and RNA concentration was determined with a 
Nanodrop spectrophotometer for the gene expression analysis. The quality of the 
RNA was monitored using an Experion automated electrophoresis station (BioRad, 
Hercules, CA) with standard sensitivity RNA chips.  Agilent labeling kits were 
utilized to amplify and generate Cy-dye labeled cRNA for hybridization to Agilent 
oligonucleotide arrays.  The samples from ponasterone A, arachidonic acid, and 
ponasterone A and arachidonic acid combination treated cells were all labeled with 
Cy-5 and compared against the Cy-3 labeled EtOH control. 
Transcript levels were assessed on each channel and quantified by Agilent 
Feature Extraction software.  This software preprocessed the data as follows: local 
background was subtracted, irregular spots were flagged, global linear regression 
(lowess) normalization was performed, and this ratio was log transformed.  Data 
was imported into TIGR MEV 3.1 software for further analysis. A supervised 
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strategy was used to identify the genes with expression profiles that were similar or 
reciprocal to SEPP1 gene expression using Pavlidis Template Matching (PTM) 
(Pavlidis and Noble, 2001).  The six genes matched most strongly with SEPP1 were 
identified and the three best annotated of these genes were used in further analyses. 
 
 
Electronic Database Analyses 
 
 Genes matched with SEPP1 expression, as measured by PTM analysis of the 
microarray data, were analyzed in GATHER.  The TRANSFAC component of 
GATHER worked to detect the presence of shared potential TFBS within the 
promoters of the genes.  Significance was measured with a Bayes factor and a 
factor greater than 6 was considered statistically significant. 
Among the six genes found to match SEPP1 expression most strongly by 
PTM analysis, the three best annotated of these were identified.  These gene names, 
as well as SEPP1, were entered into TRED.   Two kilobase sequences surrounding 
the transcriptional start sites (1700 bp upstream, 330 bp downstream) were 
retrieved in FASTA format.  These promoter sequences were entered into the 
MEME database and analyzed for homologous motifs.  Identified motifs that 
contained regions of the SEPP1 promoter and had information content greater than 
20 bits were chosen for further analysis.  The sequences of all sites represented in 
each of these motifs were entered into TESS.  Results were examined in tabular 
format to view details regarding the putative binding sites that were identified, 
including the start position, sense, similarity scores, sequence, factor name, and 
accession numbers.  TESS results were manually sorted in order to identify putative 
  
53
binding sites found within all genes represented within a particular motif.  
Evaluation of evolutionary conservation among these sites was accomplished using 
ConSite.  The genomic sequences of human and murine SEPP1 were entered into 
the ConSite database in FASTA format and these orthologous sequences were 





A custom spotted cDNA microarray was utilized to identify gene expression 
changes following induced expression of 15-LOX-1 and arachidonic acid treatment.  
Only a small number of genes were found to have changes in expression under 
these conditions, with an expression analysis showing SEPP1 to be the most 
upregulated gene on the array (Figure 2.1).  Importantly, results were only 
compared with the vehicle treated control and not compared to controls in which 
either enzyme induction or arachidonic acid treatment were controlled for 
individually. 
A commercial human whole genome microarray was run with these control 
conditions included.  Additionally, a 12-LOX expressing cell line was included for 
comparison and a 15-LOX mutant construct (15-LOX-∆I) and the LacZ gene were 
used as control cell lines.  The 15-LOX mutant lacks the C-terminal isoleucine 
responsible for coordinating the nonheme iron that functions in the enzymatic 
activity of all LOX enzymes (Chen et al., 1995).  Results suggested that activation 

































Figure 2.1   15-LOX metabolism of arachidonic acid induces SEPP1. M versus 
A plot of microarray data comparing induced 15-LOX cells in the presence of 
arachidonate for 4 hours to uninduced cells.  Induced genes (in brackets) were 





expression of SEPP1, regardless of the overexpressed gene or whether the lipid 
substrate arachidonic acid had been added (Figure 2.2).   
In order to gain information regarding the regulatory mechanisms involved in 
SEPP1 expression, multiple electronic database tools were used to search for shared 
regulatory regions between SEPP1 and co-expressed genes identified in the 
microarray results (Figure 2.3).  PTM analysis of microarray data revealed 149 
matched and 41526 unmatched genes in relation to SEPP1 expression following 
treatment of ecdysone-inducible HEK-293 cells.  This molecular signature was 
analyzed using GATHER in an attempt to identify shared TFBS annotated by 
TRANSFAC.  Results of this analysis did not yield Bayes factors greater than 6; 
therefore, annotations were not considered significant and TFBS shared among the 
genes were not identified by this method. 
This led to a search for unidentified sequence patterns within the promoters of 
the co-expressed genes.  For simplicity of analysis, the number of genes evaluated 
was reduced by identifying the six genes matched most strongly with SEPP1 
through PTM analysis and choosing the three best annotated of these for further 
analysis.  These three genes included Tissue factor pathway inhibitor 2 (TFPI2), 
Semenogelin (SEMG1), and Megalencephalic leukoencephalopathy with 
subcortical cysts 1 (MLC1).  TFPI2 is proteinase inhibitor that acts against a wide 
range of serine proteases (Chand et al., 2004).  SEMG1 is the predominate protein 
component of human semen (Lilja et al., 1989).  The exact function of MLC1 is 
unknown; however, mutations in the gene have been associated with the 








Figure 2.2 Activation of VgEcR induces host gene expression.  Pavlidis 
Template Matching of microarray data compared induced 15-LOX, 12-LOX, 15-
LOX-∆I, or LacZ cells to uninduced cells in the presence or absence of 
arachidonate for four hours.  The heat map displayed is a representation of the six 
genes that best matched the SEPP1 expression profile.  Activation of VgEcR by 
PonA was sufficient for gene expression changes regardless of the overexpressed 








Figure 2.3 Flow diagram of electronic database analyses of putative TFBS.   
Coexpressed genes were identified by microarray analysis following treatment of 
ecdyone-inducible cells with PonA.  The GATHER database worked to identify 
regulatory relationships between the coexpressed genes, but failed to find shared 
TFBS in the gene sequences.  Promoter sequences of coexpressed genes were 
collected from TRED and entered into the MEME database to identify homologous 
sequence motifs.  These homologous sequences were entered into TESS to identify 
putative TFBS.  Evolutionary conservation of motifs identified in the SEPP1 




(Leegwater et al., 2001).  These genes seem functionally unrelated to SEPP1, which 
works in selenium distribution to extrahepatic tissues (Hill et al., 2003; Renko et 
al., 2008).  Gene expression changes observed in the microarray results for these 
four genes are outlined in Table 2.1.   
In order to identify regions of sequence similarity among these four co-
expressed genes, promoter regions (2 kilobase sequences surrounding the 
transcriptional start site) of the genes were retrieved from TRED (ID #34663 for 
SEPP1, ID #39081 for TFPI2, ID #26315 for SEMG1, and ID #28529 for MLC-1) 
and searched using MEME.  Of the 10 motifs presented in the MEME results, eight 
included sequence signals from SEPP1 and three included signals from all four of 
the genes analyzed.  Each motif displayed varying degrees of sequence 
conservation with total information content ranging from 14.2 to 39.9 bits.  A 
representative block diagram is shown for a motif that included signals from all 
analyzed genes (Figure 2.4).   
For each MEME motif that included signals from SEPP1 and had information 
content greater than 20 bits, the sequences of all sites represented in the motif was 
entered into TESS.  Table 2.2 lists putative binding sites identified within each of 
the analyzed MEME motifs when these sites were found to exist in all genes 
represented within that particular motif.  Because these sites were represented 
across the coexpressed genes, they were thought to be the most likely candidates for 
functional binding sites.  Of particular interest were the putative glucocorticoid 






Fold Changes in Gene Expression of Coexpressed Genes 
 Following Treatment of Ecdysone-Inducible  
HEK-293 Cells with Ponasterone A  
 
 
 TFPI2a SEMG1b SEPP1c MLC1d 
     
15-LOX PonA 3.27 3.13 2.24 1.03 
     
15-LOX PonA+AA 3.53 3.17 2.18 1.04 
     
15-LOX-∆I PonA 2.86 4.03 2.29 2.52 
     
15-LOX-∆I PonA+AA 2.98 3.13 2.37 2.58 
     
12-LOX PonA 3.92 3.58 2.78 2.69 
     
12-LOX PonA+AA 4.24 3.68 3.27 2.96 
     
LacZ PonA 3.79 3.32 2.61 1.29 
     
LacZ PonA+AA 4.41 3.41 3.66 2.95 
     
a




 Selenoprotein P 
d














Figure 2.4 Sample MEME output.  Representative motif in which sequence from 
all four input genes are included.  The sites identified as belonging to the motif are 
indicated, with the consensus sequence shown above them.  The color-coded bar 
graph shows conservation at each position in the motif.  The level of conservation 
is measured in bits, and a sum of the bits across the motif provides information 






Representative Putative Transcription Factor Binding Sites 
Identified in the SEPP1 Promoter by TESS 
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and 6 on the SEPP1 promoter, as transcriptional activation by VgEcR involves 
binding of a heterodimer formed between GR and RXR (Saez et al., 2000).  VgEcR  
is a synthetic receptor produced by the fusion of the ligand-binding and 
dimerization domain of the Drosophila ecdysone receptor (EcR), the DNA-binding 
domain of the GR, and the transcriptional activation domain of herpes simplex virus 
VP16.  Upon exposure to ponasterone A, VgEcR dimerizes with the RXR, 
corepressors are released, coactivators are recruited, and the complex becomes 
transcriptionally active (Figure 2.5)  While the VgEcR system is not expected to 
transactivate host genes by itself, such as was observed here, changes in 
endogenous gene levels have been previously observed in mammalian cells treated 
with EcR ligands (Oehme et al., 2006; Panguluri et al., 2007). 
Phyologenetic footprinting analysis by ConSite revealed that the GR and 
RARγ sites of Motif 6 were located in a region of the SEPP1 that shares 
approximately 80% sequence homology with the murine gene (Figure 2.6).  






Understanding the mechanisms responsible for regulating gene activity is a 
primary goal of the post-genomic era of biology (Sandelin et al., 2004).  The 
function of regulatory elements is mediated by DNA-protein interactions; therefore, 
focus has centered on the identification of protein binding sites, and in particular 




Adapted from http://www.stratagene.com/manuals/217468.pdf 
 
 
Figure 2.5 Regulation of transcription by the VgEcR system.  The synthetic 
VgEcR transcription factor is a fusion of the ligand-binding domain of the 
Drosophila EcR, the DNA-binding domain of the GR, and the transcriptional 
activation domain of herpes simplex virus Vp16.  The EcR dimerizes with RXR and 
binds to multiple copies of a synthetic ecdysone-responsive element (E/GRE).  
Ligand binding of the EcR leads to the release of corepressors and recruitment of 



















Figure 2.6 Phylogenetic footprinting of SEPP1 genomic sequence. Evolutionary 
conservation of the SEPP1 gene was evaluated using ConSite.  The murine 
sequence, indicated in green, was aligned with the human sequence, indicated in 
blue.  Level of conservation was measured at each nucleotide position and reported 
as a percentage of sequence homology.  Conserved putative binding sites were also 
reported by ConSite.  The dashed boxed indicates the position of the putative GR 




approaches such as DNase footprinting, gel shift assays, and microarrays can be 
used to identify molecules working cooperatively to affect a biological process 
(Galas and Schmitz, 1978; Garner and Revzin, 1981; Schena et al., 1995), they do 
not provide direct evidence of the promoter regions controlling changes in gene 
expression. 
To aid in the discovery of TFBS, multiple computational tools for modeling 
and predicting gene regulatory elements have been developed (Elnitski et al., 2006).  
While each of these tools seem to offer their own niche capabilities, overlapping 
and complementary functions allow the various databases to be used together in a 
way that strengthens evidence identifying a binding site model within the promoter 
region of a gene or group of genes of interest.  The collaborative use of these 
databases also reduces the rate of false-positives that occurs when a single tool is 
used as the sole means for modeling and predicting binding sites (Jolly et al., 2005; 
Tompa et al., 2005). 
Despite accelerating the discovery of transcriptional regulatory mechanisms, 
the usefulness of these tools is limited by their inability to factor in the contribution 
of biological function, such as tissue-specific effects, on gene expression (Elnitski 
et al., 2006).  The cellular environment ultimately dictates which events occur 
during transcription.  For this reason, experimental confirmation of computational 
predictions is considered prudent and remains the best form of validation of in silco 
data (Elnitski et al., 2006). 
In recognizing the unique capabilities and limitations of experimental and 
computational techniques, the synergism of these two approaches becomes 
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apparent.  In results presented here, experimental data from microarray analysis 
provided information regarding genes that were coexpressed in ponasterone A-
induced HEK-293 cells.  Database analysis then identified sequence motifs shared 
between the promoter regions of these co-expressed genes and predicted TFBS 
within the sequences.  The identification of these putative sites has guided further 
analysis of the mechanisms regulating expression of SEPP1 on a transcriptional 
level.  Experimental techniques, such as promoter analyses and electrophoretic 
mobility shift assays (EMSA) were used to confirm the TFBS predictions reported 
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Selenoprotein P (SelP) is an extracellular glycoprotein that carries 
approximately 40% of plasma selenium (Akesson et al., 1994).  SelP is unique 
among the selenoproteins in that it can possess up to 10 selenocysteine residues in 
mammals (Burk & Hill, 2005).  SelP primarily functions in selenium distribution 
(Hill et al., 2003; Renko et al., 2008), with knockout mice displaying altered 
selenium distribution, particularly to the testes and brain (Hill et al., 2003; Burk et 
al., 2006).  The majority of SelP is derived from hepatic sources, however; the 
mRNA can be detected in almost all tissues, with appreciable concentrations 
observed in the kidney, heart, lung, brain, skeletal muscle, and testis (Burk & Hill, 
2005) 
The regulation of selenoprotein P gene (SEPP1) expression is an active area of 
investigation with changes in SEPP1 noted under a broad spectrum of biological 
processes.  In HepG2 cells and primary rat hepatocytes, promoter activity has been 
shown to be inhibited by cytokines including interleukin 1β, tumor necrosis factor 
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α, interferon γ, and transforming growth factor β1 (Dreher et al., 1997; Mostert et 
al., 2001).  This inhibition suggests that the SEPP1 gene product may function as a 
negative acute-phase protein in response to inflammation. Alternatively, promoter 
activity is stimulated in hepatic cells through the FOXO1a and HNF-4α 
transcription factors (Speckmann et al., 2008; Walter et al., 2008). 
In addition to inflammation, microarray analyses have revealed changes in 
SEPP1 expression during development and following alterations in the 
differentiation state of extrahepatic cells.  Elegant developmental studies have 
demonstrated SEPP1 ortholog spatiotemporal expression in both zebrafish (Thisse 
et al., 2003) and murine model systems (Lee et al., 2008).   Increased expression 
has been observed in differentiating myeloid, pulmonary, and Sertoli cells (Tabuchi 
et al., 2005; Ghassabeh et al., 2006; Wade et al., 2006).  Conversely, SEPP1 
expression is decreased with neoplastic progression from normal tissue, to 
carcinoma, to metastatic disease in cells of prostate origin (Dhanasekaran et al., 
2001).  Evaluation of SEPP1 expression in the Oncomine database (Rhodes et al., 
2004) also identifies decreased SEPP1 expression in melanoma, lung, and colon 
cancer compared to normal tissue suggesting that decreased SEPP1 expression may 
be a common feature of malignancies.  Indeed, work in colorectal cancer suggests 
that specific selenoenzymes are reduced, indicating that changes in SEPP1 is not a 
general alteration in nutrition or decreased selenium (Al-Taie et al., 2004). 
In this chapter, induction of SEPP1 in human cells stably transfected with the 
ecdysone inducible system (VgEcR-RXR) is reported.  Due to VgEcR’s 
glucocorticoid receptor DNA binding domain, as well as evidence of SEPP1 
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modulation during development and inflammation, regulation of SEPP1 by the 
glucocorticoid receptor or the retinoid X receptor was evaluated.  In addition, 
evidence exists for changes in plasma selenium levels following glucocorticoid 
administration, with both increases and decreases noted under different sets of 
conditions (Peretz et al., 1987; Marano et al., 1990; Watanabe et al., 1997).  
Although the effect of glucocorticoids on selenium levels has not been fully 
characterized, it is believed that these changes result from redistribution of selenium 
between tissue and plasma.  It is unknown what role SelP may play in this 
glucocorticoid-induced selenium redistribution.  Therefore, the glucocorticoid 
responsiveness of the SEPP1 promoter was examined in this chapter, and it was 








The HEK-293 cell line was purchased from American Type Culture 
Collection (Manassas, VA).  Advanced DMEM, T4 DNA ligase, HindIII, XhoI, and 
SstI, Accuprime Pfx DNA polymerase, SuperScript III reverse transcriptase 
reagents, OneShot Top 10 chemically competent cells, zeocin, geneticin, 
Lipofectamine 2000, and Ni-NTA agarose were purchased from Invitrogen 
(Carlsbad, CA).  Ponasterone A (PonA) was purchased from A.G. Scientific (San 
Diego, CA).  Dexamethasone (Dex) was purchased from EMD Chemicals 
(Gibbstown, NJ).  RNeasy Mini Kit and EndoFree Maxi-and Mini-prep Kits were 
obtained from Qiagen (Valencia, CA).  Lightcycler 480 SYBR Green I master mix 
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was purchased from Roche Diagnostics (Indianapolis, IN).  Biolase DNA 
polymerase, dNTPs, magnesium chloride, and NH4 reaction buffer were purchased 
from Bioline (Taunton, MA).  SYBR Green I was purchased from Cambrex (East 
Rutherford, NJ).  Human genomic DNA and the Dual Luciferase Reporter Assay 
System was purchased from Promega (Madison, WI).  NE-PER nuclear extraction 
reagents, Biotin 3’ end DNA labeling kit, and Lightshift chemiluminescent EMSA 





pVgEcR (Invitrogen) encodes the fusion transcription factor used to generate 
ecdysone-inducible cells.  pRL-RSV and pGL4.21 (Promega) were used in the 
luciferase reporter assays; pRL-RSV constitutively expresses Renilla reniformis 
luciferase, and SEPP1 promoter fragments were cloned into the pGL4.2.1 plasmid 
that contains firefly luciferase.  The pLTRluc glucocorticoid reporter plasmid and 
pDsRed-hGR glucocorticoid receptor expression plasmid were gifts from Dr. Carol 





Human embryonic kidney line HEK-293, as well as all subsequently 
engineered cells, were cultured in Advanced DMEM medium containing 2% fetal 
bovine serum and 2mM L-glutamine.  Cells were maintained at 37°C in a 
humidified incubator with 5% CO2. 
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HEK-293 were transfected with pVgEcR and selected for zeocin resistance to 
generate stable expression of the VgEcR gene product and are referred to as 293-
EcR.  293-EcR cells that conditionally express 15-LOX-1 and ∆Ile662 15-LOX-1 
were previously described (Yu et al., 2004; Cordray et al., 2007).  Conditional 
expression of LacZ in the 293-EcR was achieved using similar methods. 
An expression vector, pDsRed-hGR, that constitutively expresses a DsRed2-
labeled, functional human GR was generously provided by Dr. Carol Lim, 
University of Utah.  The 293-EcR cells were stably transfected with this expression 
vector and selected for neomycin resistance in order to study the effects of GR 
signaling in HEK-293 cells.  These cells are referred to as EcR-GR. 
 
 
Polymerase Chain Reaction (PCR) 
 
The Transcription Regulatory Element Database (Jiang et al., 2007) was used 
to identify the ~2 Kb sequence surrounding the transcriptional start site of SEPP1, 
promoter ID #34663 (1770 bp upstream of start site, 300 bp downstream) and used 
as an electronic template to generate promoter constructs.  A 1.9 Kb sequence was 
amplified from human genomic DNA by PCR using the primer pair 5’-
TAGGTACCCCAGTTCTTTCCGGTGTTCA-3’ and 5’-TACTCGAGCGCA- 
CTGGGAACTTCACCTA-3’.  The PCR product was digested with XhoI and SstI 
and cloned into the pGL4.21 luciferase reporter vector.  This construct is referred to 
as -1652 to +247 and was utilized as template DNA in subsequent PCR reactions 
used to synthesize smaller fragments of the SEPP1 promoter region of interest.  A 
HindIII digestion of the -1652 to +247 construct generated -1652 to -385 and -391 
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to +247 promoter fragments.  The fragments were cloned into the pGL4.21 vector 
following HindIII digestion.  Due to the use of the HindIII site in the pGL4.21 
vector, the -391 to +247 fragment was only subcloned in the reverse orientation, 
and despite several attempts, no colonies were obtained with this fragment in the 
forward orientation.  The -109 to +247 and the -53 to +247 fragment were 
generated using PCR and cloned into the pGL4.21 vector using XhoI and SstI 
digestions.   
Quantitative PCR was used to assess SelP mRNA expression. 293-EcR and 
EcR-GR cells were treated with 10 µM ponasterone A 24 hours prior to mRNA 
collection, and 10 nM dexamethasone was then added at 8 or 16 hours prior to 
mRNA purification.  Vehicle treatments with ethanol (EtOH) or dimethyl sulfoxide 
(DMSO) were used as controls. The Qiagen RNeasy Mini Kit was used to collect 
and purify mRNA from cells.  First strand cDNA was synthesized using Superscript 
III reverse transcriptase and these cDNA samples were run in triplicate as 1:5 
dilutions.  Standards were run in duplicate at concentrations between 103 to 108 
copies/µl and β2 microglobulin was run as a reference gene.  The SEPP1 amplicon 
consisted of the 100 bp spanning the final intron of the genomic sequence.  The 
primer pair 5’-TTCGGGCAGAGGAGAACA-3’ and 5’-CTGGCACTGGCT-
TCTGTG-3’ were used to amplify this region. Average threshold copy number was 








Site-directed Mutagenesis   
 
Putative response elements of interest were mutated using a PCR-based 
strategy. The putative GRE sequence CAAGAATGAACATTGAACT at position   
-87 of the SEPP1 promoter (GRE #1) was mutated to the sequence 
CAAGAATGACTATTGAACT using the primer 5’-GGTCACTGCAAGAA- 
TGACTATTGAACTTTGGACTATAC-3’ and its complementary sequence 
(exchanged nucleotides are bold and underlined).  The putative GRE sequence 
TCAGAGTGTGCT at position -24 of the SEPP1 promoter (GRE #2) was mutated 
to the sequence TCAGAGGATGCT using the primer 5’-GGACTATAA- 
ATATCAGAGGATGCTGCTGTGGCTTTGTG-3’ and its complementary 
sequence.  These mutations should eliminate activity of potential GRE half sites 
(Nordeen et al. 1990).  The putative retinoid responsive element sequence 
ACATTGAACTTTGG at position -73 of the SEPP1 promoter (RRE) was mutated 
to the sequence ACATCTTACTTTGG using the primer 5’-CTGCAAG- 
AATGAACATCTTACTTTGGACTATACCTGAGG-3’ and its complementary 
sequence.  The FOXO1a binding sequence GTAAACAA at position -46 of the 
SEPP1 promoter was mutated to the sequence GTAAATCA using the primer 5’-




Luciferase Reporter Assay 
 
Reporter assays were quantified using a Dual Luciferase reporter assay.  
SEPP1 promoter constructs cloned into pGL4.21 or a mouse mammary tumor virus 
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promoter reporter construct (pLTRluc) were co-transfected with the pRL-RSV 
plasmid that serves as an internal control for transfection efficiency.  Cells were 
seeded into 6-well plates at a concentration of 5 ×105 cells/well. Each well was 
cotransfected with approximately 1 µg of firefly reporter plasmid along with 50 ng 
of the pRL-RSV vector.  Twenty-four hours after transfection, medium was 
replaced.  Cells transfected with SEPP1 promoter constructs were treated with 
either 10 µM of the ecdysone analong ponasterone A, 10 nM dexamethasone, or a 
combination of both for an additional 24 hours.  Vehicle treatment with EtOH 
and/or DMSO served as negative controls.  Cells transfected with pLTRluc were 
treated with either DMSO or 10 nM dexamethasone for 24 hours.  Following 
treatments, cells were collected in 200 µl of Passive Lysis Buffer and stored at -
80°C at least overnight to allow for cell membrane disruption.  Cell lysates were 
diluted in Passive Lysis Buffer and each sample was quantified in triplicate on 
Perkin-Elmer Victor3 V plate reader.  The sequential addition of Luciferase Assay 
Reagent II and Stop & Glo reagent allowed for the measurement of firefly and 





EcR-GR cells were supplemented with 1 µM sodium selenite and treated with 
EtOH as a vehicle control, 10 µM ponasterone A, 10 nM dexamethasone, or a 
combination of both for 24 hours.  SelP was partially purified from the culture 
medium of these cells using Ni-NTA agarose. Culture medium was mixed with the 
Ni-NTA agarose and the mixture was incubated on a nutating mixer at 4°C 
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overnight.  The Ni-NTA beads, along with any bound proteins, were collected by 
centrifugation, washed twice with 500 µl cold PBS, and then mixed with loading 
buffer and separated by NuPAGE 4-12% Bis-Tris gels.  Proteins were transferred to 
a polyvinyl difluoride membrane.  Membranes were blocked with 5% nonfat dry 
milk in TBS-T and then probed for SelP (antibody specific for SelP was a gift from 
Drs. Kris Hill & Raymond Burk, Vanderbilt University).  A peroxidase conjugated 




Electrophoretic Mobility Shift Assay 
 
Nuclear fractions were collected from 293-EcR and EcR-GR using NE-PER 
nuclear extraction reagents.  Gel shift assays were run using the Lightshift 
chemiluminescent electrophoretic mobility shift assay kit.  Double-stranded 5’-
biotinylated oligonucleotides (5’-GGTCACTGCAAGAATGAACATTGAACTT- 
TGGACTATAC-3’) corresponding to the wild-type sequence of GRE #1 was used 
as a probe.  Following end-labeling with biotinylated UTP, complementary 
oligonucleotides in equimolar amounts were heated to 95°C for 1 minute, cooled to 
65°C, and then stored at -20°C.   Binding reactions were performed in a 20 µl 
volume containing 20 fmol labeled probe, 5 µg nuclear proteins, 10 mM Tris, pH 
7.5, 50 mM KCl, 1 mM dithiothreitol, 5 mM MgCl2, 2.5% glycerol, 0.05% NP-40, 
1 µg herring sperm DNA, and 1 µg bovine serum albumin.  Where indicated, 4 
pmol of unlabeled competitor probe was added to reactions.  For supershift 
experiments, 1 µg anti-glucocorticoid receptor antibody (BuGR2; Calbiochem, 
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Gibbstown, NJ) was added 10 minutes after addition of biotinylated probe and 
nuclear extract and incubated for an additional 20 minutes at room temperature.  
Reactions were then loaded onto an 8% TBE gel in 22.25% Tris, pH 8.4, 22.25% 
boric acid, 0.5 mM EDTA and electrophoresed at 22°C.  DNA was transferred to a 
positively charged nylon membrane, UV cross-linked, probed using Lightshift 





GraphPad Instat, version 3.06, was used to evaluate the statistical significance 
of the results.  Two-tailed student’s t-tests were used to determine statistical 
significance when comparing two data sets.  In cases where multiple data sets were 
compared, statistical significance was determined by one-way ANOVA with Tukey 
or Tukey-Kramer multiple comparison post hoc tests, and differences were 





Previous results using 293-EcR cells with ecdysone-inducible 15-LOX-1, 
when supplemented with an appropriate substrate, like arachidonate, show an 
inhibition of the selenoprotein thioredoxin reductase activity by ~50% (Yu et al., 
2004).  This raised the question of whether other selenoenzymes might demonstrate 
altered expression under similar conditions.  Quantitative PCR experiments 
performed using 293-EcR cells with stable, ecdysone-inducible 15-LOX-1, as well 
as the control cell lines with inducible ∆Ile662 15-LOX-1, and LacZ, demonstrated 
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enhanced expression of SEPP1 following ponasterone A treatment (Figure 3.1).  
Since SEPP1 demonstrated increased expression in all these cell lines, even without 
substrate for the 15-LOX-1, it is likely that the changes in SEPP1 expression 
resulted from components of the ecdysone-inducible system rather than a response 
to 15-LOX-1 catalysis.   
The SEPP1 promoter was examined, from -1652 to +247, based on promoter 
ID #34663 in the Transcriptional Regulatory Element Database, to determine the 
region of the promoter responsible for this ecdysone-inducible transcription.    
Fragments of the promoter were tested using the luciferase reporter assay in the 
293-EcR cells.  Fragments included -1652 to +247, -1652 to -385, -391 to +247,  
-109 to +247, and -53 to +247 (Figure 3.2A).  The greatest level of transcriptional 
activation following treatment with ponasterone A was observed on the -109 to 
+247 fragment, suggesting that a site within this region of the promoter may bind a 
component of the ecdysone-inducible system and induce transcription of SEPP1 
(Figure 3.2B).   
 VgEcR is a synthetic transcription factor that is a fusion of the ligand-binding 
and dimerization domain of the Drosophila ecdysone receptor, the DNA-binding 
domain of the GR, and the transcriptional activation domain of herpes simplex virus 
VP16.  This gene expression system is designed to activate transcription upon 
dimerization of VgEcR with RXR, and binding of the heterodimer transactivates a 
synthetic ecdysone-responsive element (Saez et al., 2000) (Figure 2.5). 
Many of the nuclear hormone receptors have similar DNA binding sites.  The 
























Figure 3.1 Quantitative PCR analysis of SEPP1 expression in HEK-293 EcR-
15-LOX and control cell lines.  Ecdysone inducible expression of 15-LOX, 15-
LOX-∆I (∆Ile662 15-LOX-1), or LacZ was achieved through a stable co-transfection 
of pVgEcR into HEK-293 cells.  Cells were treated with EtOH (white) or 10 µM 
PonA (grey) for 24 hours prior to mRNA purification.  SEPP1 expression was 
measured by quantitative PCR.  The data are presented as the mean ± standard error 
of relative gene expression changes observed over a minimum of three experiments 

















































Figure 3.2 PonA induction of SEPP1 luciferase reporter constructs.  (A) 
Schematic of SEPP1 promoter fragments that were synthesized by PCR and cloned 
into the pGL4.21 vector. (B) 293-EcR were engineered through a stable transfection 
of pVgEcR into HEK-293 cells.  293-EcR cells were transfected with SEPP1 
reporter constructs.  Twenty-four hours after transfection, medium was replaced and 
cells were treated with EtOH (white) or 10 µM PonA (grey) for an additional 24 
hours.  Cells were lysed and relative firefly luciferase activity was measured using a 
Dual Luciferase reporter assay.  Technical replicates were run in each experiment, 
and data are presented as in Figure 3.1 but representing the relative activity changes 
observed over a minimum of three distinct biological experiments and demonstrate 


































































element (the binding sites for RXR and the GR DNA binding domains are 
underlined), the GR binding sequence is TGT(T/C)CT(G/T/C) (Beato et al., 1989; 
Nordeen et al., 1990), and, for comparison, the endogenous ecdysone receptor binds 
the sequence (A/G)G(G/T)T(C/T)A (Vogtli et al., 1998; Panguluri et al., 2007).   It 
is also worth noting that RXR and HNF-4α can bind with similar affinity to direct 
repeats of (A/G)G(G/T)TCA with one base spacing (Nakshatri and Chambon, 1994; 
Nakshatri & Bhat-Nakshatri, 1998).  Due to the similarities in the response 
elements, it seemed prudent to evaluate cellular responses to both VgEcR and GR 
as well as to evaluate RXR DNA-binding sequences. 
In order to evaluate the interplay between the VgEcR-RXR system and the 
GR on the SEPP1 promoter, the 293-EcR cell line was engineered to express a 
DsRed2-labeled, functional human GR.  The pLTRluc reporter assay confirmed that 
the GR is activated by dexamethasone in these EcR-GR cells, with minimal activity 
in HEK-293 or 293-EcR cells (Figure 3.3).  To evaluate possible cross-talk between 
VgEcR-RXR and GR, ponasterone A was used to treat 293-EcR or EcR-GR cells, 
transiently transfected with pLTRluc, and only background reporter activity was 
seen (data not shown). 
When the luciferase reporter assay was run in the EcR-GR cells to test 
activation of the SEPP1 promoter constructs, the GR exerted a repressive effect on 
this promoter (Figure 3.4).  Even in the absence of dexamethasone activation, 
ponasterone A-induced activity was attenuated in the EcR-GR cells, as compared to 
293-EcR cells with no active GR.  In order to verify that these results were not due 
















Figure 3.3 Glucocorticoid receptor luciferase reporter. Stable transfection of the 
293-EcR cells with the expression vector, pDsRed-hGR produced the EcR-GR cell 
line.  HEK-293, 293-EcR, and EcR-GR cells were transfected with the mouse 
mammary tumor virus promoter reporter construct pLTRluc.  Twenty-four hours 
after transfection, medium was replaced and cells were treated with DMSO (white) 
or 10 nM Dex (grey) for an additional 24 hours.  Cells were lysed and relative 
firefly luciferase activity was measured using a Dual Luciferase reporter assay.  The 
data are presented as in previous figures of this chapter and represent triplicate 










































Figure 3.4 Glucocorticoid responsiveness of SEPP1 luciferase reporter 
constructs. HEK-293, 293-EcR, and EcR-GR cells were transfected with either (A) 
-1652 to +247 SEPP1 luciferase reporter or (B) -109 to +247 SEPP1 luciferase 
reporter.   Twenty-four hours after transfection, medium was replaced and cells 
were treated with EtOH (white), 10 nM Dex (grey), 10 µM PonA (light grey), or a 
combination of 10 nM Dex and 10 µM PonA (dark grey) for an additional 24 hours.  
Cells were lysed and relative firefly luciferase activity was measured using a Dual 
Luciferase reporter assay.  Triplicate samples were run in each experiment and data 
are presented as the mean ± standard error of relative activity changes observed 
over at least three biological replicates.  ANOVA of each cell line revealed no 
significant differences among the treatments in the HEK-293 cells but highly 
significant, p<0.0001, differences in the 239-EcR and EcR-GR cells.  Post hoc tests 
reveal differences from the vehicle control (*, p<0.05; **, p<0.01; ***, p<0.001) or 




























































































 PonA + Dex
  
88
 microscopy was used to visualize localization of the DsRed-labeled GR under the 
experimental treatment conditions.  The GR remained in the cytosol following 
EtOH or ponasterone A treatment, but was observed in the nucleus when 
dexamethasone was present.  Additionally, the GR remained localized to the cytosol 
following treatment with the nuclear export inhibitor leptomycin B (Sigma-Aldrich, 
St. Louis, MO), confirming that nuclear translocation of the receptor occurred only 
following ligand binding by dexamethasone (Appendix). 
When the EcR-GR cells were treated with 10 nM dexamethasone, promoter 
activity was repressed by ~82% on the -1652 to +247 fragment, as compared to 
vehicle control (Figure 3.4A).  Activation was repressed by ~37% on the -109 to 
+247 fragment under the same conditions (Figure 3.4B).  Simultaneous treatment of 
the EcR-GR cells with ponasterone A and dexamethasone caused attenuation of 
ponasterone A activity, with an ~84% reduction in activation observed on the -1652 
to +247 fragment as compared ponasterone A only treatment.  An ~55% reduction 
was observed on the -109 to +247 fragment under the same conditions.  In 
comparison, dexamethasone treatment was unable to exert a significant influence on 
ponasterone A activation in the 293-EcR cells, with only an ~26% reduction in 
activity observed on the -1652 to +247 fragment and an ~6% reduction observed on 
the -109 to +247 fragment.  Treatment with dexamethasone alone did not cause 
repression of promoter activity in the 293-EcR cells.  Neither ponasterone A nor 
dexamethasone exerted a significant effect on the SEPP1 promoter constructs in 
HEK-293 cells.  Repression by dexamthasone did not appear to be dose-dependent,
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as a 1000 nM dose produced similar levels of activity in the assay (data not shown).  
Additionally, while the magnitude of transcriptional activity was decreased with a 
4-hour, versus 24-hour treatment period, a similar pattern of activity was observed 
between cell lines and luciferase reporter constructs (data not shown). 
Based on the luciferase reporter assay results observed in the -109 to +247 
region, this region of the SEPP1 promoter was examined for evidence of response 
elements that could potentially serve as binding sites for GR or VgEcR, as well as 
RXR.  Two putative GREs were identified using the Transcription Element Search 
System (Schug & Overton, 1997).  These response elements are referred to as GRE 
#1 and GRE #2 and are found at position -87 and -24 of the SEPP1 promoter, 
respectively.  The precise sequences suggest that these sites may not function as 
classical GREs but appeared to best define half-sites (Nordeen et al., 1990).  In 
addition, a putative retinoid receptor binding site was identified at position -73 of 
the SEPP1 promoter, and is referred to as a putative RRE.  GRE #1 and the RRE are 
sequential with one another and together could form a potential binding site for 
VgEcR-RXR.  These sites also overlap with a previously characterized HNF-4α 
binding site in the SEPP1 promoter (Speckmann et al., 2008; Walter et al., 2008).   
In order to determine if these binding site(s) were responsible for the 
VgEcR-RXR and GR mediated effects, the luciferase reporter assay was repeated 
with SEPP1 reporter constructs in which the two putative GREs or the RRE were 
mutated (Figure 3.5A).  Despite the fact that GRE #2 was located within the -53 to 










Figure 3.5 Site-directed mutagenesis of GRE’s identified within the SEPP1 
promoter.  (A) Schematic of the two putative GREs and RRE identified within the 
-109 to +247 SEPP1 promoter fragment along with previously identified sites in the 
same region (FOXO1a and HNF-4α).  These response elements were mutagenized, 
as indicated by the bases identified with a bar, using a PCR-based strategy.  (B)  
293-EcR, and (C) EcR-GR cells were transfected with, appropriate mutant, -109 to 
+247 SEPP1 reporter constructs.  Twenty-four hours after transfection, medium was 
replaced and cells were treated with EtOH (white), 10 nM Dex (grey), 10 µM PonA 
(light grey), or a combination of 10 nM Dex and10 µM PonA (dark grey) for an 
additional 24 hours.  Cells were lysed and relative firefly luciferase activity was 
measured using a Dual Luciferase reporter assay.  Triplicate samples were run in 
each experiment and data are presented as the mean ± standard error of relative 
activity changes observed over at least three biological replicates. ANOVA of each 
cell line revealed no significant differences when GRE #1 or the RRE is mutated, 
indicating that this is the important site for transactivation in 293-EcR and EcR-GR 
cells, but significant, p<0.005, differences in the 293-EcR and EcR-GR cells when 
evaluating a mutation of GRE #2 or the FOXO1a binding site.  Post hoc tests reveal 
differences from the vehicle control (EtOH) (*, p<0.05; **, p<0.01; ***, p<0.001) 
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293-EcR cells (Figure 3.2B), a mutant form of this binding site was tested. This 
GRE more closely matched the consensus sequence, with an inverted repeat of the 
GR binding site that could accommodate a GR homodimer, and therefore, could be 
involved in GR-mediated repression. 
In both 293-EcR and EcR-GR cells, ponasterone A-induced transactivation 
was completely lost upon mutation of GRE #1 or the RRE (Figure 3.5B and 3.5C), 
with the firefly:renilla luciferase ratio being decreased by ~10 fold on the RRE 
mutant construct compared to the mutant GRE#1 reporter (data not shown).  These 
results suggest that both of these response elements serve as binding sites for the 
VgEcR-RXR transcriptional activation system. Transactivation was still observed 
with the mutated GRE #2 (Figure 3.5B and 3.5C) construct in both cell lines 
following ponasterone A treatment; however, it was slightly reduced compared to 
the non-mutated form.  This indicates that this element may also be involved in 
activation of SEPP1 through VgEcR-RXR, although to a much lesser extent than 
GRE #1 or the RRE.  The addition of dexamethasone plus ponasterone A resulted in 
attenuation of ponasterone A activity on the mutated GRE#2 luciferase reporter in 
the EcR-GR cells but not with the mutated GRE #1 reporter, indicating GRE #2 is 
not involved in the GR-mediated repression.  FOXO1a has previously been shown 
to regulate SEPP1 transcription in hepatic cells through a binding site at position -
46 of the promoter (Speckmann et al., 2008; Walter et al., 2008).  As this regulatory 
mechanism involved coordination of FOXO1a with the dexamethasone-responsive 
cofactor PGC-1α, we also evaluated SEPP1 transcription following mutation to 
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the FOXO1a site.  Neither a change in PonA-induced SEPP1 transactivation, nor 
repression by GR was observed in either 293-EcR or EcR-GR cells following 
mutation of the FOXO1a site (Figure 3.5B and 3.5C). 
Quantitative PCR results further qualified the induction of SEPP1 by VgEcR-
RXR, and its repression by the GR (Figure 3.6A).  In 293-EcR, gene induction of 
~5 fold was observed following 24 hours of ponasterone A treatment, and 
dexamethasone treatment had no effect on this induction.  Similar to the responses 
observed with the luciferase activity assays, the ability of ponasterone A to activate 
SEPP1 was attenuated in EcR-GR cells.  SEPP1 expression was reduced by ~80% 
in these cells, even in the absence of dexamethasone treatment.  Treatment with 
dexamethasone for 8 or 16 hours eliminated the ability of ponasterone A to induce 
gene expression, and led to additional repression of SEPP1 in a time dependent 
manner.  In addition, immunochemical analysis of SelP from a Ni-NTA bead pull- 
down of the media from EcR-GR cells demonstrated a similar pattern of protein 
expression (Figure 3.6B). 
To determine if the GR directly binds the GRE #1 site, electrophoretic 
mobility shift assays were utilized (Figure 3.7).  A protein:DNA complex bound to 
the GRE #1 was observed in both the 293-EcR and EcR-GR cells.  There appears to 
be minimal modulation of the amount bound in the 293-EcR cells consistent with 
the expectation of binding by VgEcR-RXR with or without ligand present as is 
expected for the ecdysone-inducible system (Figure 3.7, lanes 12-15); however, a 
dexamethasone-dependent inhibition of binding was observed in the EcR-GR cells 



























Figure 3.6 Analysis of SEPP1 expression in 293-EcR and EcR-GR cells.  (A) 
293-EcR and EcR-GR cells were treated with EtOH or 10 µM PonA 24 hrs prior to 
mRNA collection.  Beginning 8 hours after PonA was added, cells were treated 
with 10 nM Dex for 8 or 16 hours prior to mRNA purification.  SEPP1 expression 
was measured by quantitative PCR.  Triplicate samples were run in each 
experiment and data are presented as the mean ± standard error of relative activity 
changes observed over at least five biological replicates. ANOVA of each cell line 
revealed significant differences of SEPP1 expression in 293-EcR and EcR-GR 
cells, p<0.05.  Post hoc tests reveal differences from the vehicle control (*, p<0.05; 
**, p<0.01) or differences among select treatment subsets (†, p<0.05).  (B) SelP 
protein from Ni-NTA bead pull-downs from culture media demonstrate expression 
increases in EcR-GR cells following 24 hrs treatment with PonA but Dex treatment 
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Figure 3.7 Electrophoretic mobility shift assays with GRE #1.  Lane 1 contains 
the labeled GRE #1 fragment without an incubation with nuclear extract displaying 
the migration of the probe alone.  Lanes 2-5 are the GRE #1 fragment with nuclear 
extract from EcR-GR cells that were treated with EtOH, Dex, PonA, or PonA + 
Dex, respectively.  Lanes 6-8 show the same samples (without the EtOH control) 
but excess unlabeled probe is included to identify bands that represent specific 
protein:DNA complexes.  In lanes 9-11 antibodies to GR are added to determine if 
the protein:DNA complex contains GR; a supershifted band was not observed.  
Lanes 12-15 show the four conditions with nuclear extract from the 293-EcR cells; 
all lanes display a strong protein:DNA complex.  The specific complex is 
highlighted with the large arrow, the small arrows identify nonspecific bands that 
are in all lanes with nuclear extract, and FP stands for the free probe at the bottom 
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 appears to be consistent with the results from the heterologous reporter assays 
(Figure 3.4).  However, there was a failure to demonstrate that the protein:DNA 
complex contains the GR as addition of the BuGR2 antibody (Calbiochem, 
Gibbstown, NJ) directed at residues 395-411 of the GR did not produce a supershift 
or substantially alter the relative levels of protein:DNA complex.  Testing with a 
separate GR antibody (Affinity Bioreagents, Rockford IL) directed at residues 245-





The effects of supplemental selenium intake have been evaluated in multiple 
chronic and acute diseases, including cancer, cardiovascular disease, and 
inflammatory conditions such as sepsis, trauma, and burns (Clark et al., 1996; Mark 
et al., 2000; Nomura et al., 2000; Brown & Arthur, 2001; Angstwurm & Gaertner, 
2006; Angstwurm et al., 2007).  In many studies, selenium has demonstrated 
beneficial properties but the results of the Selenium and Vitamin E Trial (SELECT) 
do not support the utility of supplemental selenomethionine in prostate cancer 
prevention (Lippman et al., 2009).   The mechanism by which selenium exerts its 
effects during disease conditions is not completely understood; however, it has been 
hypothesized to be due to the antioxidant activity of selenoproteins (Diwadkar-
Navsariwala & Diamond, 2004; Irons et al., 2006). These proteins contain selenium 
incorporated as the amino acid selenocysteine during translation of the protein 
(Tujebajeva et al., 2000; Small-Howard et al., 2006; Howard et al., 2007).  
Adequate selenium intake is important in maintaining proper translation and 
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function of the selenoproteins (Bermano et al., 1996; Wingler & Brigelius-Flohe, 
1999).    Therefore, maintenance of selenoprotein function may be the mechanism 
by which supplemental selenium intake exerts a beneficial health effect.  In 
particular, the primary function of SelP is thought to be selenium distribution and 
the majority of the protein is synthesized in the liver for this purpose.  However, 
most tissues can express SEPP1; suggesting alternative functions beyond selenium 
delivery may exist for SelP (Burk & Hill, 2005) as well as the possibility of tissue 
selective modulation of SEPP1 expression.  
While the majority of SelP is expressed in the liver of adult mammals, SEPP1 
orthologs in developing fish and mammals demonstrate broad tissue expression.   
Zebrafish, who have an extensive selenoproteome, includes two SEPP1 isoforms 
encoded by distinct genes; one (sepp1a) with a selenocysteine-rich C-terminus 
containing 16 selenocysteine residues, and a second isoform (sepp1b) that lacks the 
selenocysteine-rich C-terminus (Kryukov and Gladyshev, 2000).  These genes 
demonstrate distinct spatiotemporal expression patterns throughout the development 
of the zebrafish with sepp1a displaying expression in multiple organs including the 
heart, brain and kidney, but only limited hepatic expression, while sepp1b 
demonstrates strong hepatic expression (Thisse et al., 2003).  In addition, a recent 
study of the expression of the murine ortholog of SEPP1 in mouse embryos also 
highlights a potential role of SelP in growth and developmental processes.  
Spatiotemporal expression of Sepp was observed in the central nervous system, 
limb buds, blood cells, lung, liver, intestine, testis, and developing epithelia, as well 
as in extraembryonic tissues, during organogenesis.  The authors suggest that this 
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increase in Sepp may provide antioxidant protection against the reactive oxygen 
species formed during embryogenesis, as well as provide a transplacental or 
intraembyronic selenium transport function (Lee et al., 2008).  Additional evidence 
supporting a role for SelP in growth and development includes observations from 
the SelP knockout mouse, which displays a phenotype that includes growth 
retardation, neurological impairment, and male infertility (Hill et al., 2003; 
Schomburg et al., 2003; Renko et al., 2008).  The regulatory signals responsible for 
modulating SEPP1 expression for the purpose of growth and development are 
currently under investigation.   
Recently, hepatic SEPP1 expression was shown to be controlled through 
coordination of the transcription factors FOXO1a and HNF-4α by the coactivator 
PGC-1α  (Speckmann et al., 2008; Walter et al., 2008).  Discovery of this 
mechanism introduces the idea that SEPP1 can be regulated in response to 
hormonal stimuli and may be responsive to various nuclear receptors due to the 
versatility of PGC-1α. 
Nuclear receptors are members of a large superfamily of proteins that function 
as ligand-inducible transcription factors (Germain et al., 2006; Teboul et al., 2008).  
This family contains steroid hormone receptors such as the glucocorticoid, estrogen, 
and androgen receptors, as well as receptors for thyroid hormones and retinoic acid.  
In addition, orphan nuclear receptors exist for which ligands have not been 
identified (Teboul et al., 2008). Examples of such orphan receptors include HNF-4α 
and chicken ovalbumin upstream promoter-transcription factors (Benoit et al., 
2006).  These receptors regulate gene transcription by binding to hormone response 
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elements in the promoter region of target genes.  Most receptors bind as homo- or 
hetero-dimers to response elements composed of two core hexameric motifs.  
Consensus sequences for these motifs include AGAACA for steroid receptors and 
AG(G/T)TCA for the remaining nuclear receptors (Aranda and Pascual, 2001).  
Multiple nuclear receptor types can bind these sequences and mediate 
transcriptional activity, allowing for differential control of overlapping gene 
networks (Bedo et al., 1989; Umesono et al., 1991).  Nuclear receptors have a well 
established role in growth, development and homeostasis as has been reviewed 
(Flamant et al., 2006). 
The decrease in serum selenium observed during critical illness is believed to 
result from redistribution of the micronutrient to high priority organs (Angstwurm 
and Gaertner, 2006).  The selenium distribution (Hill et al., 2003; Renko et al., 
2008) and negative acute phase functions (Dreher et al., 1997) of SelP support a 
potential role for this protein in selenium changes observed during critical illness.  
Recently, a newly developed immunoassay was used to show a decrease in SelP in 
the serum of septic patients (Hollenbach et al., 2008).  The exact mechanism 
responsible for this decreased protein expression is not known; however, the 
authors propose that it is due to proinflammatory cytokines that are induced as a 
result of the acute phase reaction occurring during sepsis, since several cytokines 
can repress SEPP1 expression (Dreher et al., 1997; Mostert et al., 2001).  The 
evidence presented here also supports a potential role for the GR in regulating 
SEPP1 expression.  Glucocorticoid responsiveness of SEPP1 could be of 
significance in critically ill patients, as these patients tend to have increased free 
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plasma cortisol levels (Hamrahian et al., 2004).  Such regulation of SEPP1 by 
glucocorticoids could serve as an alternative explanation for the changes in SelP, 
and therefore the changes in serum selenium levels, observed during critical illness.  
However, a recent study demonstrates that the decrease in SelP in the acute-phase 
response appears to be a deficit in translation rather than a transcriptional response 
(Renko et al., 2009); therefore, the data herein may be more relevant for 
development or differentiation. 
Here the VgEcR-RXR gene expression system was identified as a tool for 
studying the expression of SEPP1.  The results indicate that once activated by 
ponasterone A, VgEcR-RXR is capable of inducing transcription of SEPP1 through 
a GRE located at position -87 or a RRE at position -73 of the promoter.    In the 
EcR-GR cells, treatment with the GR agonist dexamethasone resulted in an 
attenuation of the ponasterone A-induced transcription of SEPP1 compared to 
ponasterone A treatment alone.  This suggests that once activated by 
dexamethasone, the GR can travel to the nucleus and alter VgEcR-RXR binding at 
the site identified as GRE #1.  While the EMSA failed to demonstrate GR binding 
through a supershift of the protein:DNA complex, nuclear extracts from the EcR-
GR cells do display dexamethasone-dependent modulation of the protein:DNA 
complex that was consistent with the heterologous reporter expression assays. 
When a functional GR was stably integrated to make the EcR-GR cells, a 
generalized repression of SEPP1 was observed compared to the 293-EcR cells.   
This data supports the idea that the GR may indirectly regulate expression of this 
gene, and this effect was further validated by the evaluation of the protein levels of 
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SelP expressed in the EcR-GR cells; however, it should be noted that the 
conclusions drawn from the EMSA results are limited by the absence of a supershift 
under positive control conditions.   
An indirect mechanism of GR modulation of transcription has been described 
previously through the interaction with CCAAT/enhancer-binding proteins 
(Rudiger et al., 2002).  These proteins are involved in a broad spectrum of 
biological activities including development and differentiation (Ramji & Foka, 
2002).  Whether a GR interaction with a CCAAT/enhancer-binding protein might 
be involved in SEPP1 regulation will require further study, and the precise cause for 
the repression observed in this study is unknown; however, transfection of GRs has 
previously been shown to be sufficient for the repression of hormone-responsive 
genes (Gougat et al., 2002).  
The GR usually binds DNA as a homodimer; however, it has been 
demonstrated that monomers can bind to ‘half-sites’ and modulate transactivation 
when the binding site is far as 37 base pairs from the TATA element.  The 
maximum distance at which this activity is retained is unknown; however, it was 
shown to be lost when the binding site was inserted 350 base pairs upstream from 
the transcriptional start site (Strahle et al., 1988).  The GRE #1 site identified here is 
47 base pairs 5’ to the TATA element and could potentially be mediating activation 
through this mechanism.  Alternatively, a GR monomer could potentially be 
working synergistically with another transcription factor (Strahle et al., 1988) or 
perhaps another cryptic GRE may be present within this region that has not yet been 
identified.  Another site for GR binding might explain the repression observed with 
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dexamethasone treatment as well as the reduction of the protein:DNA complex 
observed in the EMSA if GR binding would modulate the occupancy of other 
regulators of SEPP1 expression.  
The local region identified as GRE #1 is within a region that has already 
demonstrated insulin-dependent attenuation of SEPP1 expression by modulation of 
HNF-4α activity (Speckmann et al., 2008), and therefore, this could be a critical 
region that determines the expression levels of SEPP1 based on the affinity and 
availability of transcriptional regulators in different cell types.  Other genes have 
HNF-4α responsive elements that overlap with GR or RXR responsive elements 
and perhaps this allows for more intricate modulation of these genes in 
development (Crestani et al., 1998; Bailly et al., 2001).    It is unlikely that the 
effects on transactivation observed here are related to interactions with HNF-4α 
since this transcription factor is not expressed in HEK-293 cells (Lucas et al., 
2005), and it is unclear how HNF-4α-mediated SEPP1 regulation would account for 
alterations in serum selenium levels in critically ill patients since insulin sensitivity 
changes would allow for more SelP expression (Lazzeri et al., 2009).    
In addition to GREs of the -109 to +247 fragment, it appears there are other 
dexamethasone-dependent repressive elements acting within the -1652 to +247 
fragment.  Ponasterone A-induced activation is reduced on this fragment as 
compared to the -109 to +247 fragment (Figures 3.2, 3.4 and 3.5).  Plus, attenuation 
of the SEPP1 promoter was observed on the larger fragment in the EcR-GR cells 
following dexamethasone treatment, but was not observed on the smaller fragment 
(Figure 3.4).  In silico evaluation of this region identified additional potential GREs, 
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but again, these sites are primarily half-sites and do not appear to be classical 
GREs.  Furthermore, the region 5’ to -109 in the SEPP1 promoter appears to have 
additional repressive elements (Figure 3.2).  These elements are not well 
characterized and in silico evaluation did not reveal obvious potential repressive 
elements; however, one complex repeat region has demonstrated repression of 
SEPP1 expression with certain polymorphisms (Al-Taie et al., 2002).  This region 
overlaps the 5’ end of the promoter reporter construct -391 to +247 used in this 
study, and perhaps was responsible for the attenuated response observed compared 
to the -109 to +247 promoter construct.      
Finally, despite the fact that the VgEcR-RXR system is not expected to 
transactivate host genes by itself, changes in endogenous gene levels have been 
previously observed in mammalian cells treated with ecdysone receptor ligands 
(Oehme et al., 2006; Panguluri et al., 2007).  In the experiments described here, 
activation of the transcriptional machinery was shown to be sufficient for changes 
in expression of at least one host gene, SEPP1.  Due to the complex nature of 
selenoprotein translation (Tujebajeva et al., 2000; Small-Howard et al., 2006; 
Howard et al., 2007), many cell lines that are commonly used express 
selenoproteins poorly; however, HEK-293 cells have been successfully used in 
other studies for the expression of selenoenzymes (Madeja et al., 2005; Squires et 
al., 2007).  Therefore, this 293-EcR system may function as a particularly effective 
system for the study of SelP transcription and translation processes. While serving 
as a beneficial tool in the studies presented herein, the potential for this system to 
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transactivate host genes may be considered as a possible limitation to the use of this 
inducible gene expression system in other studies. 
In conclusion, data are provided supporting alternative mechanisms for 
extrahepatic regulatory mechanisms of SEPP1 expression that may help explain 
SEPP1 expression in inflammation, development and differentiation.  An 
engineered, fusion transcription factor that contains the DNA binding domain from 
GR, coupled with a strong transactivation domain, along with RXR, was used to 
identify the site responsible for the induction of SEPP1 expression.  However, these 
studies revealed that the native GR inhibits the expression of SEPP1 through an 
indirect mechanism.  Therefore, the ability of corticosteroids, and perhaps retinoids, 
to modulate SEPP1 expression may be a mechanism that could result in altered 
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SELENOPROTEIN P PROTECTS CELLS FROM LIPID  





A relationship between chronic inflammation and carcinogenesis has been 
noted in numerous malignancies, including colon cancer and hepatocellular 
carcinoma (Itzkowitz and Yio, 2004; Macarthur et al., 2004).  It is believed that 
leukocytes and other phagocytic cells involved in the inflammatory process may 
lead to an induction of DNA damage in proliferating cells through the production of 
reactive oxygen and nitrogen species (Coussens and Werb, 2002).  Additionally, 
enzymes expressed during the inflammatory process, including lipoxygenase (LOX) 
enzymes, have been shown to be upregulated in certain malignancies (Kelavkar et 
al., 2000; Gupta et al., 2001).  Specifically, 15-LOX-1 expression is directly 
proportional to severity of prostate cancer, as measured by Gleason staging 
(Kelavkar et al., 2000; Kelavkar et al., 2001).  Membrane lipids released and 
metabolized during inflammation, such as arachidonic acid (AA), have also been 
linked to various malignancies, including prostate cancer (Hursting et al., 1990).  
15-LOX-1 can metabolize arachidonic acid to reactive hydroperoxy intermediates, 
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such as 15-hydroperoxyeicosatetraenoic acid (15-HpETE), the oxidative precursor 
of 15-hydroxyeicosatetraenoic acid (15-HETE) (Natarajan and Nadler, 2004; 
Sordillo et al., 2008).  In addition, end products of lipid peroxidation have been 
implicated as being mutagenic (Ray and Husain, 2002), further contributing to 
evidence that inflammation may result in carcinogenesis through its ability to 
increase the oxidative tone of the cellular environment. 
Cells possess several enzymes that can reduce lipid peroxides. Multiple 
selenoenzymes are specifically involved in the reduction of oxidized lipids.  
Glutathione peroxidase 4 (GPx4, also called phospholipid hydroperoxide GPx, or 
PHGPX) is an essential selenoenzyme that is associated with protection from lipid 
hydroperoxides (Yant et al., 2003). Thioredoxin reductase can also reduce some 
oxidized lipids (Bjornstedt et al., 1995), as well as indirectly modulate lipid 
peroxides through the reduction of peroxiredoxins (Mitsumoto et al., 2001). The 
role of selenoprotein P (SelP) as a lipid hydroperoxidase is still being elucidated. 
SelP is one of only two selenoproteins found in the extracellular environment, with 
GPx 3 being the other (Takahashi and Cohen, 1986; Akesson et al., 1994), and one 
function is in selenium distribution (Hill et al., 2003; Renko et al., 2008).  As 
opposed to GPx4 and thioredoxin reductase, SEPP1 knockout mice are viable but 
they display altered selenium distribution (Hill et al., 2003; Burk et al., 2006).  
Besides the selenium distribution function, multiple pieces of evidence support an 
antioxidant function of SelP.  This protein has been attributed to protecting rats 
against diquat-induced liver toxicity through a decrease in lipid peroxidation (Burk 
et al., 1995).  Depletion of SelP from plasma enhances plasma protein oxidation 
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mediated by peroxynitrite-induced oxidation and nitration (Arteel et al., 1998).  In 
addition, SelP protects low-density lipoproteins from peroxidation (Traulsen et al., 
2004).  In a cell-free in vitro system, SelP has been shown to reduce phospholipid 
hydroperoxide to a greater extent than other reactive oxygen species, including 
hydrogen peroxide and tert-butyl hydroperoxide (t-BHP) (Saito et al., 1999), and 
the N-terminal domain of the protein is beleived to be responsible for this effect 
(Saito et al., 2004).  
These data suggest that an enzymatic activity of SelP may be specific for 
lipid-derived substrates, as opposed to other sources of reactive oxygen stress. The 
purpose of this study was to determine if SelP displayed lipid hydroperoxidase 
activity directed at 15-LOX-1-generated metabolites.  In this chapter, the ability of 
SelP to reduce 15-HpETE and to protect human embryonic kidney (HEK-293) cells 
from oxidation is reported. Furthermore, SelP was capable of protecting a target cell 
population from oxidation produced by cells engineered with inducible 15-LOX-1 
that were provided arachidonic acid substrate.  The evidence presented suggests 
SelP may play a role in reducing lipid hydroperoxides following membrane lipid 















The HEK-293 cell line was purchased from American Type Culture 
Collection (Manassas, VA).  Advanced DMEM, CD-293, and zeocin were 
purchased from Invitrogen (Carlsbad, CA).  Ovalbumin was purchased from Fisher 
Scientific (Pittsburgh, PA).  Ponasterone A was purchased from A.G. Scientific 
(San Diego, CA).  Arachidonic acid was purchased from NuCheck Prep (Elysian, 
MN). E. coli thioredoxin, E. coli thioredoxin reductase, and tert-butyl 
hydroperoxide were purchased from Sigma-Aldrich (St. Louis, MO).  Purified 15-
HpETE and 15-HETE were purchased from Cayman (Ann Arbor, MI), as was the 
15-HETE enzyme immunoassay.  Rat Selenoprotein P was a gift from Drs. Kris 
Hill and Raymond Burk, Vanderbilt University.  Diphenylpyrenylphosphin (DPPP) 
was purchased from Dojindo Molecular Technologies (Rockville, MD). 
 
 
Cell Culture   
 
Unless otherwise noted, the human embryonic kidney line HEK-293, as well 
as all subsequently engineered cells, were cultured in Advanced DMEM medium 
containing 2% fetal bovine serum and 2mM L-glutamine.  Cells were maintained at 
37°C in a humidified incubator with 5% CO2.  Advanced DMEM is supplied with 5 
µg/l sodium selenite (NaSeO3) and the serum contained 37 ng/ml selenium.  
Therefore, even with only 2% serum, the selenite content of this media results in 




Conditional Expression of 15-LOX-1 
 
pVgEcR (Invitrogen) encodes the fusion transcription factor used to generate 
ecdysone-inducible cells.  HEK-293 were transfected with pVgEcR and selected for 
zeocin resistance to generate stable expression of the VgEcR gene product and are 
referred to as 293-EcR.  293-EcR cells that conditionally express 15-LOX-1 were 
used as previously described (Yu et al., 2004; Cordray et al., 2007).   
 
 
Preparation and Purification of 1-Palmitoyl-2-(13-hydroperoxy- 
cis-9,trans-11-octdecadienoyl) Phosphatidylcholine (PLPC-OOH) 
 
PLPC-OOH was prepared and quantified as previously described (Saito et al., 
1999).  Briefly, PLPC was oxidized with soybean lipoxidase and resulting PLPC-
OOH was extracted with ethyl acetate.  The ethyl acetate extract was evaporated, 
dissolved in methanol, and PLPC-OOH was purified by HPLC.  PLPC-OOH was 
dissolved in methanol and stored at -20°C. 
 
 
Biochemical Enzyme Assay 
 
A NADPH-coupled reaction was used to assess the ability of SelP to reduce 
various lipid substrates.  Lipid substrates tested in the assay included 10 µM 15-
HETE, 10 µM 15-HpETE, 100 µM tert-butyl hydroperoxide, and 60 µM PLPC-
OOH.  The assay was run in a 384 well UV transparent clear bottom plate.  
Reaction mixtures contained 0.1M Tris-HCl, pH 7.4, 0.24 mM NADPH, 1mM 
EDTA, 0.025% Triton-X-100 / 0.3% sodium deoxycholate, ~0.1 Units E. coli 
thioredoxin reductase, 3.2 µg rat SelP, and appropriate lipid substrate aliquots.  
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After a 10 minute incubation at 25°C, the reaction was initiated by the addition of   
6.66 µM E. coli thioredoxin to the sample wells.  In control experiments, reactions 
mixtures without rat SelP or E. coli thioredoxin were used to evaluate the 
spontaneous reaction rates.  The oxidation of NADPH was measured by monitoring 
the absorbance at 340 nm (A340) for ~500 sec. 
 
 
Enrichment of Selenoprotein P 
 
Increased transcription and translation of SelP has previously been observed 
in 293-EcR cells treated with the ecydsone analog ponasterone A (PonA) (Rock and 
Moos, 2009).  293-EcR cells were maintained in serum-free CD-293 cell culture 
medium supplemented with 2mM L-glutamine, 1 µM sodium selenite and 10 µM 
PonA.  After 3 days, supernatant was collected from the cells following 
centrifugation at 250 x g for 5 minutes.  The supernatant was concentrated ~20 fold 
using a Centricon Plus-70 centrifugal filter (Millipore) with a 30-kDa cutoff 
membrane. This concentrated media retains SelP, and was used in experiments to 
evaluate antioxidant properties of SelP.  As a control, supernatant was collected and 
concentrated from vehicle (EtOH) treated 293-EcR cells. 
Inductively coupled plasma (ICP) spectrometry (Perkin Elmer Optima 3100 
XL) was used to determine the selenium content in the concentrated cell culture 
media.  The instrument was calibrated using SPEX CertiPrep Laboratory 
Performance Check Standard 1 (Metuchen, NJ).  The results were collected in parts 
per million (ppm) using WinLab32 for ICP software (v. 3.4.0.0253) and then 
converted to Se concentration.  Selenium content of the concentrated supernatants 
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was used to calculate SelP concentration of the supernatant based on the assumption 
that there are 10 selenium atoms per molecule of SelP.  Protein expression was 
verified by immunoblotting.  The supernatant collected from PonA-treated cells was 
referred to as (+) SelP, while that collected from EtOH-treated cells was referred to 
as (-) SelP.   
 
 
Measurement of Lipid Hydroperoxides 
 
Lipid hydroperoxides were measured using DPPP, a molecular probe that 
becomes fluorescent upon oxidation by lipid hydroperoxides (Takahashi et al., 
2001). HEK-293 cells were plated on a 384-well tissue culture plate at a 
concentration of 18,000 cells/well.  Cells were labeled with 100 µM DPPP or 
DMSO control and were incubated overnight.  Cells were supplemented with (+) 
SelP supernatant at a concentration of 60 nM SelP.  An equivalent amount of (-) 
SelP concentrated supernatant was also tested, as was 100 nM sodium selenite,
 
and 
selenium-sufficient blank control medium containing 5 µg/l sodium selenite.  
Immediately following the addition of these supplements, cells were treated with 0-
100 µM 15-HpETE, 30 µM 15-HETE or EtOH control.  Because some variability 
in results were observed between batches of the hydroperoxy lipids purchased from 
Cayman, all reported results were tested from the same batch number of 15-HpETE 
(13250-6) or 15-HETE (156030-19).  Fluorescent intensities following excitation at 
351 nm were measured at the emission wavelength of 380 nm with a Perkin-Elmer 







EcR-15-LOX cells were seeded on a 24-well plate at a concentration of 1 ×105 
cells/well.  After 24 hours, culture medium was changed to serum-free CD-293 
supplemented with 2 mM L-glutamine and 0.1% ovalbumin.  Cells were treated 
with 10 µM ponasterone A for 24 hours, followed by a 2-hour treatment with 60 
µM arachidonic acid.  Vehicle treatment with EtOH served as controls for both 
treatment conditions.  Culture medium was collected and 15(S)-HETE levels were 





Following collection of culture medium for enzyme immunoassay evaluation, 
EcR-15-LOX cells were resuspended in lysis buffer, sonicated at 4°C, centrifuged 
at 14,000 rpm for 10 minutes, and supernatant was collected.  For EcR-15-LOX 
samples, 5 µg of the supernatant protein were separated by SDS-PAGE.  For 
enriched supernatant samples collected from 293-EcR cells, 15 µl of the sample 
were separated by SDS-PAGE.  Following separation, proteins were transferred to a 
nitrocellulose membrane and membranes were probed for 15-LOX-1 (Cayman 
Chemical, Ann Arbor, MI) or SelP (gift from Kris Hill & Raymond Burk).  A 
peroxidase conjugated secondary antibody was used to detect chemiluminescence 











EcR-15-LOX cells were plated in a 384-well tissue culture plate at 6,000 
cells/well.  Cells were treated with 10 µM ponasterone A and incubated overnight.  
HEK-293 cells were grown in 25cm2 flasks in serum-free CD-293 cell culture 
medium supplemented with 2 mM L-glutamine and 0.1% ovalbumin.  These cells 
were labeled with 100 µM DPPP or DMSO control. After 24 hours, DPPP-labeled 
HEK-293 cells, or unlabeled controls, were added into the wells with the EcR-15-
LOX cells at a concentration of 18,000 cells/well.  Cells were allowed to recover 
for 1 hour prior to the addition of (+) SelP at 60 nM SelP or (-) SelP control 
supernatant.  Immediately following the addition of the concentrated supernatant, 
cells were treated with 60 µM arachidonic acid.  Vehicle treatment with EtOH 
served as controls for both ponasterone A and arachidonic acid treatments.  Thirty 
minutes after arachidonic acid addition, fluorescent intensities were measured with 





GraphPad Instat, version 3.06, was used to evaluate the statistical significance 
of the results.  Statistical significance was determined by one-way ANOVA with 
Bonferroni multiple comparison post hoc tests, and differences were considered 











The ability of SelP to reduce PLPC-OOH through a NADPH-coupled 
biochemical assay has been described previously (Saito et al., 1999; Takebe et al., 
2002).  Similar methods were followed to test the ability of SelP to reduce 15-
HpETE and 15-HETE.  Because 15-HpETE was previously shown to inhibit the 
activity of mammalian thioredoxin reductase 1 (Yu et al., 2004), E. coli, rather than 
mammalian, thioredoxin reductase and thioredoxin were used in this assay.  The E. 
coli form of this enzyme does not possess a C-terminal selenocysteine (Gromer et 
al., 2004) such as that found to be responsible for covalent binding of electrophilic 
lipids on the mammalian enzyme (Cassidy et al., 2006).  An NADPH-coupled 
showed that activity of the E. coli enzyme was not inhibited by 15-HpETE (data not 
shown).  NADPH oxidation was used as an indirect measure of the hydroperoxidase 
activity of SelP.  Nonenzymatic NADPH oxidation rates were observed when 
thioredoxin was not added to the reaction mixtures and did not show substrate 
selectivity.  NADPH oxidation when SelP was not added to the reaction mixtures 
reflects activity by the E. coli thioredoxin system and substrate preferences for t-
BHP and 15-HpETE was observed.  However, with complete reaction mixtures, the 
PLPC-OOH was the best substrate as measured by the most NADPH oxidation 
(Figure 4.1).  15-HpETE was the next best substrate, with ~70% of the activity 
observed with the PLPC-OOH substrate. However, ~50% of that activity may be 
contributed by the thioredoxin system coupled in this reaction.  Essentially no 



















Figure 4.1 Lipid hydroperoxidase activity as measured in a NADPH-coupled 
reaction.  (A) NADPH oxidation was used as an indirect measure of the 
hydroperoxidase activity of SelP against various lipid substrates (Sub).  The E. coli 
thioredoxin reductase (TrxR) system was used to enzymatically reduce SelP as 
oxidized (ox) lipid substrates became reduced.  (B) NADPH oxidation was 
measured in each reaction mixture base, described in the Methods, with t-BHP, 15-
HETE, 15-HpETE, or PLPC-OOH as potential substrates as well as the vehicle 
control (DMSO).  Each substrate was tested with a complete reaction mixture, or 
mixtures lacking either SelP or thioredoxin (Trx).  The SelP activity in the complete 
reaction mixtures with the 15-HpETE and PLPC-OOH substrates were significantly 
different from the other conditions (***, p<0.001).  The NADPH oxidation was 
increased with t-BHP and 15-HpETE substrates in the mixtures without SelP (-
SelP) (†††, p<0.001) indicating that the E. coli thioredoxin system utilized had 









































































































Since SelP-mediated activity was observed, experiments were run to 
determine whether the activity of SelP observed in the biochemical assay could be 
translated to a cell-based system.  SelP was derived from the supernatant of 
ponasterone A treated 293-EcR cells and selenium content of concentrated 
supernatant was determined by ICP spectrometry. Increased selenium content was 
observed in the (+) SelP supernatant versus (-) SelP (0.285 ppm vs. 0.066 ppm).  
The (-) SelP concentrated media selenium content was comparable to the 
background level of selenium measured in the CD-293 media when it was not 
concentrated (data not shown).   The SelP content in these media were confirmed by 
immunoblotting, which showed considerable SelP expression in (+) SelP 
supernatant, but minimal SelP (generally <5% of the induced media) in the (-) SelP 
supernatant (Figure 4.2).  Using the assumption of ten selenium atoms per molecule 
of SelP (Burk and Hill, 2005), the (+) SelP supernatant was calculated to have a 
concentration of ~360 nM SelP, while the (-) SelP was calculated as ~80 nM SelP; 
however, this media may have an even lower SelP content as this selenium content  
was similar to the defined CD-293 media selenium content.  
A fluorescent-based assay (DPPP) was used to detect lipid hydroperoxide 
levels following exposure of HEK-293 cells to the reactive lipid metabolite 15-
HpETE.  With cells grown in selenium-sufficient medium, the cellular oxidiation 
was evaluated from 0-240 minutes. Under all treatment conditions, cellular 
oxidation reaches its maximum after approximately 25-30 minutes of 30 µM 15-
HpETE exposure.  SelP enriched media consistently demonstrated a reduction of 














Figure 4.2 Assessment of selenium and SelP content in concentrated media.  
Left: ICP analysis of selenium (Se) content in media samples; (+) SelP represents 
media from cells induced to express SelP by ponasterone A while (-) SelP 
represents media from cells treated with EtOH (vehicle control).  The selenium 
difference between these concentrated media is highly significant (***, p<0.001).  





































































Figure 4.3 SelP protects HEK-293 cells from oxidation by the pharmacological 
addition of 15-HpETE.  (A) Time course oxidative changes measured by DPPP 
fluorescence following 30 µM 15-HpETE addition in cells with standard media 
(blank, square), 100 nM sodium selenite (NaSeO3, circle), concentrated control 
media ((-) SelP, up triangle), and SelP enriched media ((+) SelP, down triangle). 
The (+) SelP condition is statistically different at all time points (p<0.001).  (B) 
Dose response of 15-HpETE oxidative changes measured by DPPP fluorescence 
(left), as well as 15-HETE at 30 µM (right). The (+) SelP condition is significantly 



































































































































resulted in a dose-dependent increase in DPPP fluorescence and the cells with SelP 
enriched media demonstrated significant protection from oxidation at 30 and 100 
µM 15-HpETE (Figure 4.3B). The addition of SelP reduced relative DPPP 
fluorescence compared to both standard (blank) medium and (-) SelP controls 
(~12% and ~7% reduction, respectively).  Since some studies, with viability as an 
outcome, have shown that both SelP and 100 nM sodium selenite can improve 
viability following oxidative stress (Steinbrenner et al., 2006a; Steinbrenner et al., 
2006b), the effect of selenium supplementation with 100 nM sodium selenite was 
also tested in this assay.  However, in this case, the addition of sodium selenite 
exerted an oxidative effect, as evidenced by an increase in relative DPPP 
fluorescence as compared to standard (identified as blank) control medium 
following 15-HpETE addition.  In addition, no increase in DPPP fluorescence was 
observed following treatment with 30 µM of the less oxidative 15-HETE lipid 
metabolite (Figure 4.3B). 
To determine if SelP could protect cells from oxidation following 15-LOX-1 
catalysis of arachidonate, overexpression of 15-LOX-1 was achieved using an 
ecdysone-inducible gene expression system (Figure 4.4A).  Following addition of 
arachidonic acid, the enzymatic activity of 15-LOX-1 was confirmed through 
detection of 15-HETE by enzyme immunoassay.  Production of the metabolite 
increased significantly following treatment of cells with the combination of 
ponasterone A and arachidonic acid, but was observed at only a minimal level 
under control conditions (Figure 4.4B).  DPPP was used to detect lipid 















Figure 4.4 SelP can protect target cells from the oxidation by effector cells 
following 15-LOX-1 catalysis of arachidonate.  (A) Inducible expression of 15-
LOX-1 in 293-EcR cells with integrated 15-LOX-1. Four conditions are evaluated; 
vehicle control (EtOH), ponasterone A (PonA), arachidonic acid (AA), and the 
combination ponasterone A and arachidonate (PonA+AA).  (B) Production of the 
15-LOX-1 metabolite 15-HETE under the four conditions just described.  (C) 
Protection from oxidation, as measured by DPPP fluorescence, with the addition of 
SelP enriched media, (+) SelP, compared to the control concentrated media, (-) SelP 





































































































transcellular assay in which DPPP-labeled HEK-293 cells were added onto EcR-15-
LOX cells allowed for the measurement of lipid hydroperoxides in cells distant 
from those that were responsible for metabolizing arachidonic acid.  In having lipid 
metabolites move through the extracellular environment prior to acting on DPPP-
labeled cells, the ability of the predominantly extracellular SelP to reduce the 
reactivity of these metabolites was able to be evaluated.  DPPP fluorescence of the 
HEK-293 cells increased following treatment of EcR-15-LOX cells with the 
combination of ponasterone A and arachidonic acid as compared to control 
conditions (Figure 4.4C).  The addition of 60 nM SelP attenuated this increase in 





The health effects of selenium have been studied in multiple disease states, 
including cancer, cardiovascular disease, and inflammatory conditions (Clark et al., 
1996; Mark et al., 2000; Nomura et al., 2000; Brown and Arthur, 2001; Angstwurm 
and Gaertner, 2006; Angstwurm et al., 2007).  Benefits of supplemental selenium 
intake are believed to be due to antioxidant activity of selenoenzymes (Diwadkar-
Navsariwala and Diamond, 2004; Diwadkar-Navsariwala et al., 2006; Irons et al., 
2006); proteins capable of redox reactions through selenium atoms incorporated as 
the amino acid selenocysteine (Tujebajeva et al., 2000; Small-Howard et al., 2006; 
Howard et al., 2007).  Recent clinical trials have provided conflicting results 
regarding many of the selenium-based health claims.  Specifically, the anti-cancer 
benefit from selenium appears to exist only for individuals with low serum 
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selenium levels (Bleys et al., 2008).  Earlier dietary supplementation studies 
demonstrated a decrease of cancer incidence that was most pronounced in 
individuals with lower serum selenium levels (Clark et al., 1996).  Additionally, 
serum selenium levels have been shown to be inversely correlated to the incidence 
of certain cancers (Clark et al., 1993; Mark et al., 2000; Nomura et al., 2000).  
Recent results of the Selenium and Vitamin E Trial (SELECT) did not support the 
utility of supplemental selenomethionine in prostate cancer prevention in selenium 
sufficient individuals (Lippman et al., 2009). Still, the antioxidant activity of 
selenoenzymes are likely important in human health. 
While protection against oxidative injury by the glutathione peroxidases have 
been extensively characterized (Arthur, 2000; Steinbrenner and Sies, 2009), the 
antioxidant activity of SelP is less well characterized.  Biochemical data have 
supported a role for SelP as a phospolipid hydroperoxidase (Saito et al., 1999; 
Takebe et al., 2002).  However, the reducing capacity of SelP in this assay was 
measured to be two orders of magnitude lower than activity observed by 
phospholipid hydroperoxide GPx (Ursini et al., 1985), suggesting that the 
contribution of SelP as an antioxidant protein might be minimal as compared to 
other selenoproteins.   
This study attempted to directly link SelP and the reduction of lipid 
hydroperoxides derived from 15-LOX-1 catalysis.  This study extends work that 
demonstrated that selenium supplementation of endothelial cells produce 
significantly higher 15-HETE to 15-HpETE ratios, while selenium deficiency 
increased oxidation of arachidonic acid to 15-HpETE (Weaver et al., 2001).  This 
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activity appears to be distinct from GPx4 modulation of lipoxygenase pathways 
involved in cell death (Seiler et al., 2008).  Further evidence supporting a lipid 
hydroperoxidase function of SelP in a cell-based system includes a report that lipid 
hydroperoxides are increased in myofibroblasts when SelP expression is knocked 
down (Kabuyama et al., 2007).  Loss of SelP also led to apoptosis and decreased 
cell viability through activation of c-Jun N-terminal kinases in this model.  In 
endothelial cells and astrocytes, SelP has been shown to protect against t-BHP-
induced cytotoxicity when cells were maintained in selenium deficient medium 
(Steinbrenner et al., 2006a; Steinbrenner et al., 2006b).  SelP protected against cell 
death to the same extent as selenium supplementation with 100 nM sodium selenite 
and this effect was attributed to increased expression and activity of cytosolic GPx.  
Both SelP and sodium selenite increased this antioxidant protein, and the use of a 
GPx specific inhibitor, counteracted SelP-mediated cytoprotection.   
Here it is shown that when HEK-293 cells were maintained in selenium-
sufficient medium, 60 nM SelP reduced lipid hydroperoxides following exposure of 
the cells to 15-HpETE.  This SelP concentration is considerably higher than that 
required to protect endothelial cells (0.6 nM) or astrocytes (2 nM) from the 
oxidative damage of t-BHP (Steinbrenner et al., 2006a; Steinbrenner et al., 2006b).  
The normal physiological concentration of SelP in selenium-replete human serum is 
estimated at 50 nM (Mostert, 2000).  A decrease to less than 5% of selenium-replete 
values has been observed in animals with severe selenium deficiency (Yang et al., 
1989; Nakayama et al., 2007).   This suggests that the discrepancy in SelP 
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concentration required to exert antioxidant effects may be related to whether cells 
are maintained under selenium -sufficient or -deficient conditions. 
The results presented here also show that reduction of lipid hydroperoxides in 
HEK-293 cells was achieved when SelP and 15-HpETE were added concurrently. 
In addition, short-term treatment with sodium selenite leads to increased oxidative 
tone in the cells, as reflected by an increase in lipid hydroperoxides following 
simultaneous addition of sodium selenite and 15-HpETE.  Protection of endothelial 
cells and astrocytes against t-BHP-induced cytotoxicity required pre-incubation 
with SelP or sodium selenite and no protection was observed in endothelial cells if 
SelP and t-BHP were added simultaneously (Steinbrenner et al., 2006a; 
Steinbrenner et al., 2006b).  This delayed effect would account for the time required 
to synthesize cytosolic GPx, the enzyme ultimately responsible for SelP-mediated 
protection in this model. The reduction of lipid hydroperoxides that was observed 
following short-term treatment with SelP likely represents direct enzymatic activity 
of the protein, rather than a genomic effect requiring the transcription and 
translation of secondary genes such as glutathione peroxidase.   
The cellular protection from oxidation by lipid hydroperoxides afforded by 
SelP observed in this study, while significant, was modest (only a 7-12% reduction 
as compared to control conditions).  This level of antioxidant activity by SelP could 
be a consequence of the extracellular localization of this protein.  Intracellular 
reduced glutathione protects endothelial cells against 15-HpETE-induced cell injury 
and stimulates the conversion of 15-HpETE to 15-HETE (Ochi et al., 1992).  
Specifically, phospholipid hydroperoxide GPx has been shown to reduce the 
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hydroperoxy ester lipids formed by 15-LOX-1 metabolism (Schnurr et al., 1996) 
and is capable of inhibiting the activity of lipoxygenase enzymes (Huang et al., 
1999). If intracellular selenoproteins including glutathione peroxidases are the 
primary source of antioxidant defense against the products of lipid metabolism, it is 
possible that the reactivity of these metabolites is minimized prior to reaching the 
extracellular environment, therefore reducing the need for SelP to act as a 
detoxifying protein. 
In conclusion, SelP has been shown to reduce lipid hydroperoxides in HEK-
293 cells after exposure to 15-HpETE.  This was observed following 
pharmacological treatment with the metabolite, as well as endogenous production 
through ecdysone-inducible expression of 15-LOX-1.  These results provide 
evidence that the lipid hydroperoxidase activity of SelP initially observed in 
biochemical assays also occurs in a cell-based model of 15-LOX-1 catalyzed 
arachidonic acid metabolism.  By reducing lipid hydroperoxides following cell 
membrane metabolism, SelP may serve to decrease oxidative tone of tissues under 
inflammatory conditions.  This could provide protection against the toxic effects of 
lipid peroxidation, leading to a decrease in DNA damage and mutations and 
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Selenium has been linked to potential beneficial health effects in multiple 
disease states, including cancer, cardiovascular disease, and inflammatory 
conditions (Clark et al., 1996; Mark et al., 2000; Nomura et al., 2000; Brown & 
Arthur, 2001; Angstwurm & Gaertner, 2006; Angstwurm et al., 2007); however, 
recent clinical trials have provided conflicting results that have brought into 
question the safety and efficacy of selenium supplementation (Bleys et al., 2008; 
Lippman et al., 2009; Stranges et al., 2007).  Beneficial effects of supplemental 
selenium intake have been attributed to antioxidant activity of selenoenzymes 
(Diwadkar-Navsariwala and Diamond, 2004; Diwadkar-Navsariwala et al., 2006; 
Irons et al., 2006); proteins capable of electron transfer through selenium atoms 
incorporated as the amino acid selenocysteine (Tujebajeva et al., 2000; Small-
Howard et al., 2006; Howard et al., 2007).  SelP is an extracellular glycoprotein that 
plays a vital role in delivering selenium to extrahepatic tissues (Akesson et al., 
1994; Hill et al., 2003; Renko et al., 2008).  An antioxidant function has also been 
observed for this protein (Burk et al., 1995; Arteel et al., 1998; Saito et al., 1999; 
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Traulsen et al., 2004; Steinbrenner et al., 2006a; Steinbrenner et al., 2006b).  
Through an increased understanding of the mechanisms regulating selenoprotein P 
expression and activity, it could be possible to gain insight into the way in which 
selenium exerts its physiological effects. 
For this reason, the experiments presented in this dissertation were designed 
to test the hypothesis that mechanisms regulating the expression of selenoprotein P 
provide for modulation of this protein so it may function to provide antioxidant 
protection in extrahepatic tissues.  These studies characterized the regulation of 
selenoprotein P through glucocorticoid response elements and determined the role 
of selenoprotein P in regulating the cellular oxidative stress induced by reactive 
hydroperoxylipid intermediates.  This chapter will summarize the major findings of 
these experiments.  A brief discussion of the findings, as well as suggested future 





Chapters 2 and 3 of this dissertation focused on characterizing the regulation 
of SEPP1 through both VgEcR and GR.  First, multiple electronic databases were 
utilized in order to identify putative TFBS within the SEPP1 promoter.  
Identification of putative glucocorticoid and retinoid responsive elements supported 
the usefulness of these bioinformatic tools, as transcriptional activation by VgEcR 
involves binding of a heterodimer formed between GR and RXR (Saez et al., 2000).  
Both a putative GRE at position -87 and a putative RRE at position -73 of the 
SEPP1 promoter were found to be necessary for transactivation of the SEPP1 
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promoter by VgEcR.  These sites overlap with an active HNF-4α site involved in 
modulating SEPP1 expression, suggesting this may be an important regulatory 
region of the promoter potentially capable of promiscuous binding by nuclear 
receptors.  A direct binding site for GR was not identified on the SEPP1 promoter 
and it appears that SEPP1 repression may be mediated through an indirect 
mechanism of the GR at GRE #1. 
Antioxidant activity of SelP against reactive hydroperoxylipid intermediates 
was evaluated through the experiments presented in Chapter 4.  Enzymatic 
reduction of 15-HpETE, but not 15-HETE, was observed in a NADPH-coupled 
biochemical assay.  SelP was also effective at reducing lipid hydroperoxides 
following exposure of cells to 15-HpETE.  This was observed both when the 
protein and metabolite were added simultaneously and in a transcellular assay 
where 15-LOX-1 was actively metabolizing arachidonic acid.  While the effects 
were modest, these results directly link SelP and the reduction of lipid 
hydroperoxides derived from 15-LOX-1 catalysis.  This provides further evidence 
of the antioxidant activity of SelP and suggests that the toxic effects of ROS formed 
during inflammation could be reduced when SelP is present at physiological 





Despite the beneficial effects that have been noted, it appears that the data 
regarding selenium supplementation is conflicting and inconclusive.  This 
highlights the difficulty in translating results from in vitro and animal models to 
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clinical effects in humans.  In addition, variability in the nutritional status and 
predisposing disease factors among different human populations makes it difficult 
to establish correlations in the available clinical data.  Therefore, further studies are 
required in order to fully elucidate the mechanism and extent of selenium’s health 
effects. 
Because the benefits of supplemental selenium intake are believed to be due to 
antioxidant activity of selenoproteins, it is thought that optimal health outcomes are 
achieved when the trace element is available in a supply adequate to prevent it from 
becoming the limiting factor in selenoprotein synthesis.  As the major selenium 
supply protein of the body, SelP plays an important role in ensuring that adequate 
tissue selenium levels are available for proper Sec translation and selenoprotein 
synthesis.  Understanding the regulatory and functional mechanisms of SelP can 
therefore provide evidence of the way in which selenium is distributed and utilized 
within the body. 
Despite the fact that the VgEcR system is not expected to transactivate host 
genes by itself, induction of SEPP1 was observed when this system was activated 
by PonA in HEK-293 cells.  In an attempt to determine the mechanism responsible 
for this unexpected effect, electronic database analyses were used to identify 
putative TFBS in the SEPP1 promoter.  While these methods identified binding 
sites that appeared likely candidates for mediating activation by VgEcR, in the end, 
these sites were approximately 13 base pairs downstream from the GRE and RRE 
shown to be responsible for transactivation.  However, the TESS-identified GRE 
within Motif 6 of the MEME output did in fact correspond to a previously 
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characterized FOXO1a site (Speckmann et al. 2008; Walter et al. 2008), lending 
support to a role for bioinformatics in identifying biologically relevant gene 
features. While these in silico techniques can identify candidate binding sites, it 
should be recognized that their use is just one step in the process of characterizing 
protein binding sites in genes.  The inability of these tools to identify the actual 
sites responsible for transcriptional activity observed here highlights the importance 
of using experimentation to verify outcomes of electronic database analyses. 
In addition to HNF-4α, the GR has now also been shown to play a role in 
regulating SEPP1 expression.  Regulation of SEPP1 by nuclear receptors 
(Speckmann et al. 2008; Rock and Moos 2009), as well as spatiotemporal 
expression during embryogenesis (Thisse et al. 2003; Lee et al. 2008), supports a 
role for this protein in developmental processes.  It is unclear whether such a 
function is newly evolved or has been conserved across species.   
Due to the proximity of GRE #1 and RRE to the candidate GRE and RARγ 
binding sites identified in Chapter 2, these active sites fell within the evolutionarily 
conserved region of SEPP1 identified by ConSite analysis.  In phylogenetic 
footprinting of human sequences, rodents are the most common species used for 
comparison as studies have revealed only a small portion of the non-coding regions 
are conserved at this evolutionary distance.  Additionally, these two species show 
high similarity in distinguishable segments of the genome, while being flanked by 
apparently random sequence (Lenhard et al., 2003; Miziara et al., 2004).  For these 
reasons, the ConSite analysis described in Chapter 2 evaluated evolutionary 
conservation between the human and murine SEPP1 genes.  Once GRE #1 and 
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RRE were shown to be necessary for transcriptional activation of SEPP1 by 
VgEcR, conservation of the sequence was evaluated across a greater number of 
species ranging in evolutionary distance from humans.  This was accomplished 
using the University of California, Santa Cruz (UCSC) Genome Browser.  This 
database is a collection of genome assembly sequence data and integrated 
annotations for a large number of organisms (Kuhn et al., 2009).  The browser 
represents annotations as a series of horizontal tracks laid out over the genome 
(Kent et al., 2002).  The Conservation track displays the results of a Multiz 
alignment, providing a view of the evolutionary relatedness of sequences across a 
wide range of animals (Kuhn et al., 2009).  Sequence conservation across species as 
divergent as the primate, mouse, dog, elephant, opossum, and chicken was observed 
when the reverse compliment of the SEPP1 promoter region corresponding to GRE 
#1 and RRE was queried (Figure 5.1).  In particular, bases identified in Chapter 3 as 
being responsible for VgEcR transactivation were highly conserved.  These results 
support the idea that this region is an important regulatory region of the promoter; 
however, it should be noted that with the exception of the chicken, all species 
identified within this phylogenetic analysis are mammals, so it is unknown whether 
this regulatory region is conserved in lower vertebrates. 
Zebrafish express two SelP isoforms, each encoded by a distinct gene.  One 
isoform shares sequence and structural similarities with the full length human 
protein, while the other lacks a Sec-rich C-terminus (Kryukov & Gladyshev 2000).  
These two isoforms are also observed in pufferfish and correspond to the rat 




















Figure 5.1 Phylogenetic footprinting of GRE #1 and RRE binding sites. The 
University of California, Santa Cruz (UCSC) Genome Browser was used to 
evaluate evolutionary conservation of the GRE #1 and RRE sequences responsible 
for VgEcR transactivation of the SEPP1 promoter. The browser represents 
annotations as a series of horizontal tracks and the Conservation track displays the 
results of a Multiz alignment.  Sequence conservation was observed across multiple 
mammalian species, as well as the chicken, for the reverse compliment of the 
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species supports the hypothesis of differential functions between the two domains 
of human SelP. 
The N-terminal domain of SelP is thought to be responsible for the 
antioxidant activity of this protein, while data support a selenium distribution 
function for the C-terminal domain (Saito et al., 2004).  The C-terminal domain is 
critical in preventing the developmental defects observed in SEPP1 knockout mice, 
including neurological and fertility impairments (Hill et al., 2007). Additionally, 
transgene expression of hepatic SEPP1 resolves the knockout phenotype (Renko et 
al., 2008).  Therefore, while evidence of the antioxidant activity of SelP continues 
to accumulate, it is clear that the selenium distribution effect of this protein is of 
paramount importance in preventing developmental defects.   
It is unclear whether there is interplay between the antioxidant activity of SelP 
and the proposed role of this protein in development.  Evidence suggests that 
selenium is necessary for mammalian embryonic development (Bedwal and 
Bahuguna, 1994), a process that generates ROS through aerobic and anaerobic 
metabolic pathways (Ornoy, 2007).  While antioxidant systems are still developing 
at this stage of growth, expression of cytosloic GPx and superoxide dismutase 
mRNA has been noted in mouse embryos (El-Hage and Singh, 1990; Baek et al., 
2005; Yon et al., 2008).  Developmental studies have also shown spatiotemporal 
expression of a SEPP1 ortholog in both zebrafish (Thisse et al., 2003) and murine 
model systems (Lee et al., 2008).  It was suggested that these expression patterns 
may correspond to a function for SelP in protecting against embryonic oxidative 
damage (Lee et al., 2008). 
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Figure 5.2 outlines a proposed mechanism by which SelP is regulated and 
subsequently exerts its physiological effects.  In considering this model, it is 
important to recall that the majority of SelP is synthesized in the liver for the 
purpose of delivering selenium throughout the body (Burk and Hill, 2005).  Studies 
in knockout animals have shown that delivery to the brain and testes are of 
particular importance (Hill et al., 2003; Burk et al., 2006), and ApoER2 appears to 
be responsible for SelP uptake into these tissues (Olson et al., 2007; Burk et al., 
2007).  As the C-terminal domain is necessary to prevent neurological and fertility 
impairments under selenium-deficient conditions (Hill et al. 2007), it appears that 
this region of the protein is responsible for supplying selenium to the tissues once 
uptake has occurred.  It seems likely that SelP derived from the liver is degraded in 
these tissues for the purpose of increasing the supply of selenium available for the 
synthesis of other selenoproteins.  This supply could also facilitate local de novo 
synthesis of SelP, providing a mechanism for tissue-specific selenium retention, 
such as is observed in the brain and testes during selenium-deficient conditions 
(Burk et al., 1972; Behne et al., 1988). 
This proposed mechanism of selenium delivery by SelP to the brain and testes 
is in contrast to distribution in the kidney, where the C-terminal domain of SelP is 
not required (Hill et al., 2007).  In this case, it seems the N-terminal domain is 
sufficient, introducing the idea that the various SelP isoforms could function 
differentially in tissues throughout the body.   
Under selenium-sufficient conditions, where selenoprotein synthesis is not 

















Figure 5.2 Proposed mechanism of selenoprotein P regulation and activity.  
SEPP1 is upregulated in cells undergoing differentiation.  Additionally, the 
transcription factor hepatocyte nuclear factor 4α (HNF-4α) has been shown to 
increase SEPP1.  Multiple cytokines repress SEPP1 and expression of SelP is 
decreased in sepsis, leading to the suggestion that SelP functions as an acute phase 
protein during inflammation.   Once synthesized, SelP is excreted into the 
extracellular space.  SelP produced in the liver primarily functions in selenium 
delivery to extrahepatic tissues, where the protein supplies selenium for the 
production of additional selenoproteins.  Additionally, de novo synthesis of SelP 
can occur in extrahepatic tissues, providing a mechanism for selenium retention 
during deficiency.  In selenium-sufficient conditions, where selenoprotein synthesis 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































unclear whether this might be a tissue-specific effect.  While the magnitude of 
SelP’s antioxidant activity was nominal in HEK-293 cells, a more pronounced 
effect could potentially be observed in cells of neuronal or testicular origin, tissues 
where the protein seems to be of vital importance.  The Sec in the N-terminal region 
of the protein is proposed to be responsible for the antioxidant activity of SelP; 
however, catalytic reduction of this Sec would be required in order to maintain this 
activity.  The enzymatic system reponsible for catalyzing this reduction has yet to 
be identified, but could potentially involve the selenoprotein enzyme thioredoxin 
reductase.  Alternatively, it is speculated that there could be a role for the nine C-





The GR was shown to modulate SEPP1 expression, but direct binding of this 
protein to the promoter was not observed in the studies presented here.  Therefore, 
further studies are required in order to fully characterize the mechanism responsible 
for GR regulation of SEPP1.  Greater GR-mediated repression of ponasterone A-
induced activation was observed on the -1652 to +247 fragment of the SEPP1 
promoter as compared to the -109 to +247 fragment (Figures 3.2, 3.4 and 3.5), 
suggesting additional repressive elements exist within the full length promoter.  
While an attempt to identify potential putative binding sites responsible for this 
activity revealed additional GRE half-sites, no site corresponding to the classical 
GRE consensus sequence was found.  Based the activity of half-sites observed on 
the  -109 to +247 fragment, it seems prudent to test the activity of the additional 
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half-sites in the full promoter through similar methods, including site-directed 
mutagenesis.  Additionally, a complex DNA-repeat region within the SEPP1 
promoter has demonstrated repression of SEPP1 expression with certain 
polymorphisms (Al-Taie et al., 2002).  These simple sequence repeats can function 
as binding sites for regulatory proteins (Kashi et al., 1997), and thus, mutant forms 
of this site should be evaluated to determine its effect on GR-mediated SEPP1 
expression.   
While conclusions are limited by the absence of a positive control in the 
EMSA, data presented here seem to support an indirect role of the GR in regulating 
expression of SEPP1.  An indirect mechanism of GR modulation of transcription 
has been described previously through an interaction with CCAAT/enhancer-
binding proteins (Rudiger et al., 2002) and subsequent  in silico analysis of the 
SEPP1 promoter revealed the presence of a CCAAT/enhancer-binding protein site 
immediately downstream from GRE #1.  Studies aimed at evaluating the interplay 
between these two transcription factors may provide further evidence of the way in 
which SEPP1 is regulated.  Because CCAAT/enhancer-binding proteins are 
involved in development and differentiation (Ramji & Foka, 2002) these studies 
could also provide insight into the function of SelP during development. 
There are multiple ways in which to build upon the evidence of SelP’s 
antioxidant activity.  Data presented here are specific in terms of characterizing 
activity against a particular oxidative metabolite (15-HpETE).  However, the ability 
to consider this data in a biological context is limited by the fact that it does not 
account for the complex nature of the inflammatory process in which multiple 
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reactive metabolites are formed.  In the future, studies could be run which consider 
this complexity.  One approach would be to test alternative eicosanoids formed 
during inflammation as substrates for SelP, using assays similar to those described 
here.  Alternatively, the role of SelP on downstream effects of eicosanoid signaling 
could be evaluated.  For example, metabolites of LOX- and COX-catalysis have 
been shown to oxidize peroxiredoxins (Cordray et al., 2007).  These proteins play a 
role in regulating ROS signaling through their reduction of hydrogen peroxide in 
cells (Wood et al., 2003).  SelP was found to be ineffective at preventing the 
oxidation of peroxiredoxins in metabolically active EcR-15-LOX cells (data not 
shown); however, SelP protection could potentially be observed in a transcellular 
system, where oxidation is measured in cells distant from those forming the reactive 
metabolites.   
Other general markers of oxidative stress, such as DNA adduct formation or 
apoptosis could also be assessed.  Specifically, SEPP1 knockdown has been shown 
to induce apoptosis through activation of c-Jun N-terminal kinases (Kabuyama et 
al., 2007), so further characterizing the role of SelP in this pathway would be a 
logical approach for future studies.  The nuclear factor kappa beta pathway is 
another pathway under ROS-mediated control that could be evaluated in such 
studies (Bubici et al., 2006). 
Immunohistochemistry has previously been used to visualize SelP tissue 
expression (Burk et al. 1997).  This method could potentially be useful in 
determining whether there is tissue-specific expression of SelP isoforms.  
Antibodies specific for each of the isoforms would need to be developed in order to 
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run such a study; however, the outcomes could provide new insight into the tissue-
specific functions of SelP.   In addition to providing information on the function of 
extrahepatic SelP, this study could also work to further characterize differential 
functions of the SelP isoforms. 
Finally, using animal models would be an extremely effective method for 
translating the results of in vitro experiments to a more complete biological context.  
The development of SEPP1 knockout mice has provided a very useful tool for 
running such experiments.  Application of an in vivo model of inflammation in 
these animals could provide a wider context in which to consider the antioxidant 
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Localization of GR following treatment of EcR-GR cells.  EcR-GR cells 
were treated with 10nM Dex, 10µM PonA, or vehicle control for 24 hours in 
order to evaluate GR localization under experimental treatment conditions.  
Treatment with 10nM of the nuclear export inhibitor leptomycin B was also 
tested.  Phase contrast images appear on the left and fluorescent images appear 
on the right.  Black bars are equal to 1 millimeter.  Fluorescently-labeled GR is 
shown in white and nuclei are indicated by arrows.  Cytoplasmic localization of 
GR is observed with vehicle control, PonA, and leptomycin B treatments.  
Nuclear localization was observed only following the addition of Dex, 
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